Introduction {#section5-1758835919877726}
============

Gastric cancer is the third leading cause of cancer-related mortality worldwide, and more than half of the cases occur in East Asia.^[@bibr1-1758835919877726],[@bibr2-1758835919877726]^ It is estimated that over 950,000 cases were newly diagnosed in 2012, while 720,000 fatalities were reported, highlighting its relatively poor prognosis.^[@bibr1-1758835919877726]^

For early localized gastric cancer cases, surgery has been recognized as the optimal therapeutic option owing to its curability.^[@bibr3-1758835919877726],[@bibr4-1758835919877726]^ Nonetheless, for those bearing incurable factors, such as locally advanced inoperable, recurrent, or metastatic gastric cancer, systemic therapy is often used as the preferred palliative treatment among cancer patients, which offers survival benefits compared with supportive treatments alone.^[@bibr5-1758835919877726]^

Currently, owing to its survival benefits and satisfactory safety profile, fluoropyrimidine and platinum-based doublet is widely recommended as the preferred first-line systemic regimen against advanced gastric cancer. Specifically, fluorouracil (5-FU) or capecitabine plus cisplatin, capecitabine plus cisplatin or oxaliplatin, S-1 or capecitabine plus cisplatin, and S-1 or capecitabine plus oxaliplatin are the first choices recommended by National Comprehensive Cancer Network (NCCN),^[@bibr5-1758835919877726]^ European Society for Medical Oncology (ESMO),^[@bibr6-1758835919877726]^ Japanese,^[@bibr7-1758835919877726]^ and Chinese^[@bibr8-1758835919877726]^ guidelines, respectively. In terms of fluoropyrimidine and platinum-based triplet, no consensus has been reached despite several phase III studies reporting positive survival results when comparing fluoropyrimidine and platinum-based triplet with the doublet regimen.^[@bibr9-1758835919877726][@bibr10-1758835919877726]--[@bibr11-1758835919877726]^ Higher toxicity is the major concern about the clinical application of the three-drug regimen, therefore current guidelines only recommend the three-drug regimen for patients with better performance status (PS).^[@bibr5-1758835919877726],[@bibr6-1758835919877726]^ Furthermore, the addition of targeted medications displayed comparable survival benefits against fluoropyrimidine and platinum-based triplet alone,^[@bibr12-1758835919877726][@bibr13-1758835919877726][@bibr14-1758835919877726]--[@bibr15-1758835919877726]^ adding more options on potential alternatives of fluoropyrimidine and platinum-based doublet in terms of preferred first-line systemic regimens.

However, comprehensive evidence of this topic is still scarce. Although three previously published high-quality systematic reviews had reported relevant results, each of them had specific imperfections. Wagner *et al*. updated their systematic review based on studies up to June 2016 (*n* = 64).^[@bibr16-1758835919877726]^ However, this systematic review was only quantitatively synthesized by pairwise meta-analyses rather than hierarchical network meta-analysis. Meanwhile, it only included first-line chemotherapy while excluding studies with targeted medications. Song *et al*. published a systematic review and pairwise meta-analysis based on studies up to December 2015 (*n* = 11), which was also an noncomprehensive review since it only included studies with molecular-targeted first-line therapy.^[@bibr17-1758835919877726]^ Moreover, Ter Veer *et al*. conducted a systematic review with network meta-analysis based on studies until June 2015 (*n* = 65).^[@bibr18-1758835919877726]^ Nonetheless, this systematic review contained both advanced esophageal and gastric cancer patients, while it discussed first-line chemotherapy only. Therefore, those systematic reviews were lopsided, outdated, or inadequate in their use of hierarchical rankings, which urged us to provide an updated and by far the most comprehensive systematic review and network meta-analysis.

Methods {#section6-1758835919877726}
=======

Registration and guidelines {#section7-1758835919877726}
---------------------------

The protocol of our systematic review and network meta-analysis had been published in PROSPERO (CRD42018084951). The design, conduct, and writing of this systematic review and network meta-analysis was strictly in accordance with the requirements from the PRISMA Checklist for Network Meta-analysis and Cochrane Handbook 5.1. Each step was conducted by two investigators of our research group. Any discrepancy was resolved by a third investigator.

Search strategy {#section8-1758835919877726}
---------------

Electronic databases including PubMed, Web of Science, Cochrane Central Register of Controlled Trials, and Embase were examined comprehensively. In addition, we also thoroughly searched major databases for meeting abstracts, including American Society of Clinical Oncology (ASCO) and ESMO Meeting Library. The searching process started on 1 March until 4 October 2018, covering possible indexes published from inception to October 2018. Both the abstract and the main text of the retrieved entries were rigorously assessed in order to guarantee the accuracy of selection. Furthermore, in the case of omission, the reference lists of three previously published high-quality systematic reviews were also reviewed.^[@bibr16-1758835919877726][@bibr17-1758835919877726]--[@bibr18-1758835919877726]^ The full electronic search strategy is presented in the [supplementary material](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726).

Selection criteria {#section9-1758835919877726}
------------------

Studies that simultaneously met the following inclusion criteria were eligible (PICOS framework).

1.  Participant: patients with previously untreated advanced gastric cancer, including locally inoperable, recurrent, and metastatic cases. Studies that contained both gastric and esophageal cancer cases were eligible. However, if other types of malignancies existed such as pancreatic cancer, it was not qualified unless subgroup data were offered.

2.  Intervention: different first-line systemic treatments against advanced gastric cancer, including chemotherapy and targeted medications. Regarding chemotherapeutic types, since intraperitoneal chemotherapy was still controversial among different countries, we only included oral and intravenous chemotherapeutic regimens. Moreover, the comparisons between different regimens of chemotherapy were qualified while the comparisons between different dosages or methods of administration by the same chemotherapeutic regimen were not eligible. Comparisons between auxiliary therapeutics (such as anti-inflammatory medications, nutritional supportive methods, unspecified herbal medicine, and immunomodulators) were also not qualified.

3.  Comparator: 'FP2' (fluoropyrimidine plus platinum-based doublet), 'FC2' (5-FU plus cisplatin doublet), and 'XC2' (capecitabine plus cisplatin doublet) were common comparator nodes of network meta-analysis under different scenarios.

4.  Outcome: time-to-event overall or progression-free survival (PFS) data \[hazard ratio (HR) or Kaplan--Meier curves\] were mandatory, while results of objective response rate (ORR) and adverse events were dispensable.

5.  Study design: phase II and phase III randomized controlled trials reported from inception to October 2018 without language limitations. We only included the one with the longest follow-up period among different reports of the same registered trial.

Studies were excluded from systematic review owing to the following reasons.

1.  Could not incorporate into network calculation among unselected population.

2.  Sequential first-line therapy ([Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

Risk of bias assessment {#section10-1758835919877726}
-----------------------

The quality of each eligible study was evaluated by The Cochrane Risk of Bias Tool. The entire scale was constituted by seven domains, namely random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias.^[@bibr19-1758835919877726]^ According to the criteria in Cochrane Handbook 5.1, each domain could be judged as any of the three levels, low risk, unclear risk, or high risk of bias. If the majority of items were judged as low risk of bias, then the entire methodological design of network meta-analysis was regarded as low risk of bias, and vice versa. Here, studies were defined to be low quality if four or more items were scored as high risk of bias.

Data extraction {#section11-1758835919877726}
---------------

Predesigned forms were utilized to collect and organize the original data. General information, survival, and safety data were extracted from the main text, tables, survival curves, or [supplementary materials](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726), which had been cross-checked by two different investigators in our team before quantitative synthesis.

Nodes, baseline parameters, and endpoints {#section12-1758835919877726}
-----------------------------------------

Our major principle for node classifications was to combine similar and less-significant regimens together so that sample size and the advantages of direct randomization could be enhanced, and meanwhile also individualize the clinically significant components based on their known mechanisms to lower the heterogeneity and maintain clinical availability. For general analysis among the unselected population, all nodes were in the form of alphanumeric combination. Each type of alphanumeric combination was selected based on the clinical significance and availability. Since leucovorin was routinely considered as a chemo-modulator, it was not calculated into a separate node. The node abbreviations in the general analysis were as follows: F, fluoropyrimidine; P, platinum; R, targeted medication; T, taxane; I, irinotecan; A, anthracycline; M, methotrexate; E, etoposide; Y, mitomycin-C; S, best supportive care; U, nitrosourea; 1, monotherapy; 2, doublet; 3, triplet. For example, 'FP3R' suggested that this regimen was a fluoropyrimidine plus platinum-based triplet plus one targeted medication, while 'F1' indicated that it was a fluoropyrimidine monotherapy. Meanwhile, different drugs within each regimen were orderly listed according to their clinical significance for systemic therapy (fluoropyrimidine, platinum, leucovorin, taxane, other drugs), which helped to eliminate the possible false classification of the same regimen into two different nodes. For additional analysis among unselected population, similar rationale had been applied. Moreover, since fluoropyrimidine and platinum were crucial components for gastric cancer systemic treatments with different subtypes inside each category that might function differently, we individualized diverse types of fluoropyrimidine and platinum when combining them into separate nodes. All abbreviations of nodes in additional analysis were as follows: S, S-1; C, cisplatin; X, capecitabine; R, targeted medication; O, oxaliplatin; F, 5-FU; H, heptaplatin; 1, monotherapy; 2, doublet; 3, triplet. For instance, 'XC3' was the node for capecitabine plus cisplatin-based triplet.

Unselected patients were those without specific pathological positivity, in contrast to those featuring specific positivity such as HER-2 positive gastric cancer. Since most studies were completed *via* multinational cooperation, the leading country of each study was defined by the nationality of its first corresponding author, who usually led the project. Age referred to the median age of overall population. Here, region referred to the source region of patients that had been analyzed in the studies. Western regions included Europe, North America, and Australia, while eastern regions usually referred to East Asian countries including Japan, South Korea, and China. If the study contained patients from both western and eastern regions, or patients from other areas of the world (such as South America), it was regarded as a versatile region. Visceral involvement suggested the metastatic involvement of liver and lung. In term of measurability, those nonmeasurable but assessable patients were also included as measurable cases. Owing to the potential disparity of efficacy in terms of different tumor locations and histological types, ratios between gastric cancer and gastroesophageal junction cancer, as well as intestinal type and diffused type were collected, respectively. Usually, patients with gastric cancer should significantly outnumber those with gastroesophageal junction cancer.

The primary endpoint was overall survival (OS), while secondary endpoints included PFS, ORR, hematological adverse events, and nonhematological adverse events. OS and PFS were defined as the time from randomization to death from any cause and the time from randomization to disease progression or death from any cause, respectively. ORR was the percentage of patients with complete and partial response. The hematological adverse events included leukopenia, neutropenia, anemia, thrombocytopenia, and other relevant events such as febrile neutropenia and infection with neutropenia. The remaining adverse events were categorized as nonhematological adverse events. We only counted grade 3 or higher (National Cancer Institute Common Terminology Criteria for Adverse Events) adverse events owing to their clinical significances. For early studies that failed to use this numerical grading system, we collected severe-toxicity adverse events in the nonhematological category and leukocyte count \<2000/μl, platelets \<50,000/μl, or hemoglobin \<9.5 g/dl were collected in the hematological category.

Statistical analysis {#section13-1758835919877726}
--------------------

HRs and 95% confidence intervals (95% CIs) were used as the effect size for OS and PFS. Risk ratios (RR) and 95% CIs were applied as the effect size for ORR, hematological and nonhematological adverse events. If survival data or its CI was not directly provided, we estimated the values from the Kaplan--Meier curves by methods described elsewhere.^[@bibr20-1758835919877726]^ In terms of adverse events, the total amount of grade 3 or higher adverse events were used for calculation, instead of the number of patients suffering grade 3 or higher adverse events.

As was known to all, the prominent strength of network meta-analysis was to provide a hierarchical ranking for multiple arms even without direct comparisons.^[@bibr21-1758835919877726]^ This key feature reflected on and highlighted the two fundamental assumptions of network meta-analysis, known as transitivity and consistency.^[@bibr22-1758835919877726]^

When the head-to-head results of A *versus* C and B *versus* C were respectively provided, then the hypothesis of transitivity also validated a statistical comparison between A and B. However, it required comparable general features within each node as the prerequisite condition to eliminate selection bias and justify statistical connections among indirect arms.^[@bibr23-1758835919877726]^ Since all included studies were randomized controlled trials without significant methodological heterogeneity, the baseline parameters were the crucial factors to determine the clinical heterogeneity and therefore transitivity. We carefully compared the main baseline features of different arms within each node and eliminated those with significant differences by sensitivity analysis. Apart from clinical and methodological heterogeneity, we also evaluated statistical heterogeneity of the network meta-analysis, which was known as the overall degree of disparity within the same pairwise comparison.^[@bibr24-1758835919877726]^ The *I*^2^ statistic was the chief indicator of statistical heterogeneity, with values of \<25%, 25--50%, and \>50% indicating low, moderate, and high heterogeneity, respectively. In addition, the *Q* statistic of heterogeneity and its *p* value also facilitated the assessment of statistical heterogeneity. If the *p* value of the *Q* statistic was less than 0.05, it suggested that there was significant heterogeneity.

On the other hand, the consistency, another crucial assumption for network meta-analysis, referred to the statistically consistent results between direct and indirect effect sizes regarding the same comparison. Significant differences between direct and indirect calculations might indicate inconsistency within the network meta-analysis while also suggest the unsuitability for transitivity.^[@bibr25-1758835919877726]^ Here, we employed several methods to assess the network consistency, including the comparison between direct and indirect results as well as the *Q* statistic. We performed a pairwise meta-analysis *via* both fixed-effects and random-effects calculations to generate direct results before network meta-analysis. Concerning the same therapeutic comparison, the results were regarded as consistent if the 95% CI of both pairwise and network meta-analysis significantly overlapped. Meanwhile, the *Q* statistic of inconsistency was another statistical indicator to numerically estimate the consistency within the comparisons, whose *p* value (\<0.05) could suggest a significant inconsistency between pairwise and network meta-analysis. Both consistency and homogeneity were crucial bases to offer reliable outcomes by network meta-analysis. If inconsistency or significant heterogeneity occurred, we deleted the original data from the most inconsistent or heterogeneous pairwise comparisons to examine whether the results remained unchanged, otherwise it was not appropriate for pooled analysis.^[@bibr24-1758835919877726],[@bibr26-1758835919877726]^

For the network calculation of general analysis, 'fluoropyrimidine plus platinum' (FP2) was chosen as the common comparator since it was the regimen preferred by different guidelines. A network plot and comparison-adjusted funnel plot were used to display the network structure and examine the publication bias across the included trials, respectively, where the more symmetrical it was, the lower the probability of publication bias the merged results would have.^[@bibr27-1758835919877726],[@bibr28-1758835919877726]^ We conducted the random-effects network meta-analysis based on a frequentist model, with either HR or RR as the effect size. A network forest plot or league table were used to demonstrate the entire regimens with their relative CIs. In addition, we also utilized P-score to rank all regimens based on their network estimates. The closer the P-score moved to 1, the better the regimen. Sensitivity analysis was performed to detect the stability of pooled outcomes, which included using fixed-effects model and deleting studies with significant clinical heterogeneity. For the network calculation of additional analysis, '5-FU plus cisplatin' (FC2) was chosen as the common comparator since they were recommended by NCCN guidelines, while the remaining statistical methods were similar to those of the general analysis.

Both pairwise and network meta-analysis were conducted in R software 3.4.3, assisted by STATA 14.0 in terms of graphical functions.

Role of the funding source {#section14-1758835919877726}
--------------------------

The sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results {#section15-1758835919877726}
=======

Literature retrieval {#section16-1758835919877726}
--------------------

After screening through 15,262 preliminary records, a total of 119 randomized controlled trials were eligible for inclusion in our systematic review ([Figure 1](#fig1-1758835919877726){ref-type="fig"}). Among 119 eligible trials, 94 studies were included in the general analysis of unselected population, 39 studies were selected into the additional analysis of unselected population (including 22 studies overlapping with general analysis), while 8 trials were systematically reviewed in terms of specific pathological positivity. Both systematic review and network meta-analysis were conducted among unselected population, irrespective of general or additional analysis. However, owing to the limited number of eligible studies, we only performed systematic review for studies concerning specific pathological positivity.

![Selection flow chart for network meta-analysis.](10.1177_1758835919877726-fig1){#fig1-1758835919877726}

General analysis: baseline features and transitivity {#section17-1758835919877726}
----------------------------------------------------

Overall, 94 randomized controlled trials were included in the general analysis, containing a total of 17,976 participants. Japan (*n* = 19), USA (*n* = 15), and China (*n* = 12) were the top three leading countries. A total of 52 studies recruited patients from western region, while 37 and 5 studies featured patients from the eastern region and versatile region, respectively, displaying a relatively balanced geographical distribution between eastern and western regions. 'Fluoropyrimidine plus platinum doublet' was the most frequent node in the network (*n* = 45), followed by 'fluoropyrimidine plus platinum-based triplet' (*n* = 31), and 'fluoropyrimidine monotherapy' (*n* = 28). The majority of the studies featured populations with a median-age around 60 and male-dominant sex ratio. Predominantly, patients were metastatic measurable cases and had a PS of either 0 or 1. Meanwhile, the ratio of visceral or peritoneal involvement, primary locations (dominant proportion of gastric cancer cases) and histological types were largely comparable across different studies. Therefore, the demographic characteristics of included trials were generally comparable. Several studies might introduce potential heterogeneity owing to incompatible baseline features with other studies, such as recruiting elderly patients (\>70 years old),^[@bibr12-1758835919877726],[@bibr29-1758835919877726][@bibr30-1758835919877726][@bibr31-1758835919877726]--[@bibr32-1758835919877726]^ containing esophageal,^[@bibr13-1758835919877726][@bibr14-1758835919877726]--[@bibr15-1758835919877726],[@bibr29-1758835919877726],[@bibr31-1758835919877726],[@bibr33-1758835919877726][@bibr34-1758835919877726][@bibr35-1758835919877726]--[@bibr36-1758835919877726]^ fake registration identifier,^[@bibr37-1758835919877726]^ nonmeasurable cases only,^[@bibr38-1758835919877726]^ and peritoneal metastasis only^[@bibr39-1758835919877726]^ ([Table 1](#table1-1758835919877726){ref-type="table"}). The influence on pooled results by these studies was further detected in sensitivity analysis.

###### 

Baseline characteristics of eligible studies for general analysis (unselected population).

![](10.1177_1758835919877726-table1)

  Study                                             Leading country   Registration                   Phase            Enrollment                        Regimen                                                            Node                                      Sample size                               Age                                       Gender (M/F)                              Region                                    Metastatic (Y/N)                          Visceral involvement (Y/N)                Peritoneal involvement (Y/N)   Prior resection (Y/N)   Measurable (Y/N)          PS (0/1/2)      Location (G/J)                    Histological type (I/D)   OS-HR                                         PFS-HR                                        ORR (P/T)   hAE (E/T)          non-hAE (E/T)      Journal                                PMID
  ------------------------------------------------- ----------------- ------------------------------ ---------------- --------------------------------- ------------------------------------------------------------------ ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------ ----------------------- ------------------------- --------------- --------------------------------- ------------------------- --------------------------------------------- --------------------------------------------- ----------- ------------------ ------------------ -------------------------------------- -------------------------------------------
  Yamada 2018                                       Japan             UMIN000007652                  III              April 2012---March 2016           S-1 plus cisplatin plus docetaxel                                  FP3                                       370                                       Adult                                     NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        0--1            Gastric                           259/428                   0.99 (95% CI, 0.85--1.16)                     0.99 (95% CI, 0.86--1.15)                     219/370     [245/370-2]{.ul}   [26/370-1]{.ul}    J Clin Oncol                           J Clin Oncol 36, 2018 (suppl; abstr 4009)
  S-1 plus cisplatin                                FP2               371                            208/371          [140/371-2]{.ul}                  [27/371-1]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Muro 2018                                         Japan             NCT02539225                    II               October 2015---October 2017       S-1 plus oxaliplatin plus ramucirumab                              FP2R                                      96                                        Adult                                     NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        0--1            Gastric and junction              NA                        NA                                            1.07 (95% CI, 0.86--1.33)                     32/55       NA                 NA                 J Clin Oncol                           J Clin Oncol 36, 2018 (suppl; abstr 4036)
  S-1 plus oxaliplatin                              FP2               93                             27/54                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Lu 2018                                           China             NCT01015339                    III              December 2009---February 2014     Capecitabine plus paclitaxel                                       FT2                                       160                                       56.6                                      115/45                                    Eastern                                   151/9                                     71/89                                     8/152                          51/109                  Measurable                0--2            92/68                             40/40                     0.88 (95% CI, 0.69--1.13)                     0.91 (95% CI, 0.71--1.16)                     69/160      100/158            24/158             Gastric Cancer                         29488121
  Capecitabine plus cisplatin                       FP2               160                            56.2             118/42                            142/18                                                             76/84                                     4/156                                     50/110                                    97/63                                     31/35                                     46/160                                    91/147                                    65/147                                                                                                                                                                                                                                                                                                                                            
  Fuchs 2018                                        USA               NCT02314117                    III              January 2015---May 2017           5-FU/capecitabine plus cisplatin plus ramucirumab                  FP2R                                      326                                       58.9                                      214/112                                   Versatile                                 Metastatic                                NA                                        NA                             NA                      Measurable                0--2            Gastric and junction              NA                        0.96 (95% CI, 0.80--1.16)                     0.75 (95% CI, 0.61--0.94)                     134/326     [125/326-2]{.ul}   [32/326-1]{.ul}    J Clin Oncol                           10.1200/JCO.2018.36.4_suppl.5
  5-FU/capecitabine plus cisplatin                  FP2               319                            60.1             215/104                           116/319                                                            [131/319-2]{.ul}                          [5/319-1]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Matsuyama 2018                                    Japan             UMIN000006179                  II               August 2011---September 2015      S-1 plus docetaxel                                                 FT2                                       30                                        18--75                                    NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      **Non-measurable** ^\*^   0--2            Gastric                           NA                        0.62 (95% CI, 0.34--1.13)                     0.70 (95% CI, 0.40--1.21)                     NA          [15/30-2]{.ul}     [4/30-3]{.ul}      J Clin Oncol                           10.1200/JCO.2018.36.4_suppl.119
  S-1 plus cisplatin                                FP2               31                             [11/31-2]{.ul}   [10/31-3]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Iqbal 2017                                        USA               NCT01498289                    II               February 2012---March 2018        5-FU plus oxaliplatin plus leucovorin                              FP2                                       99                                        Adult                                     NA                                        Western                                   Metastatic and locally unresectable       NA                                        NA                             NA                      Measurable                0--2            **Gastric and esophageal** ^\*^   NA                        0.82 (95% CI, 0.61--1.10)                     0.70 (95% CI, 0.52--0.93)                     33/80       NA                 NA                 J Clin Oncol                           10.1200/JCO.2017.35.15_suppl.4009
  Docetaxel plus irinotecan                         TI2               104                            23/86                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Li 2017                                           China             ChiCTR-TRC-08000167            II               April 2008---September 2012       5-FU plus leucovorin plus irinotecan                               FI2                                       71                                        53                                        50/21                                     Eastern                                   65/6                                      33/38                                     NA                             49/22                   Measurable                12/25/35        Gastric                           Balanced                  1.23 (95% CI, 0.87--1.75)                     1.23 (95% CI, 0.89--1.69)                     6/54        22/71              12/71              Oncotarget                             29228659
  5-FU plus oxaliplatin plus leucovorin             FP2               74                             52               54/20                             67/7                                                               21/53                                     49/25                                     10/29/35                                  7/74                                      27/74                                     14/74                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Hwang 2017                                        South Korea       NCT01470742                    III              August 2010---October 2014        Capecitabine plus oxaliplatin                                      FP2                                       24                                        **75** ^\*^                               18/6                                      Eastern                                   15/9                                      NA                                        NA                             11/13                   Measurable                [20/4]{.ul}     Gastric                           NA                        0.58 (95% CI, 0.30--1.12)                     0.32 (95% CI, 0.17--0.61)                     10/24       4/24               10/24              J Geriatr Oncol                        28119041
  Capecitabine                                      F1                26                             **77** ^\*^      16/10                             15/11                                                              15/11                                     [20/6]{.ul}                               8/26                                      5/26                                      7/26                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Hall 2017                                         UK                ISCTRN33934807                 II               June 2009---January 2011          Capecitabine plus oxaliplatin plus epirubicin                      FP3                                       17                                        **74** ^\*^                               13/4                                      Western                                   17/0                                      NA                                        NA                             NA                      NA                        0/11/6          **10/2/5** ^\*^ **-E**            Balanced                  1 *versus* 2: 1.24 (95% CI, 0.39--3.94)       1 *versus* 2: 0.83 (95% CI, 0.36--1.93)       5/17        NA                 14/17              Br J Cancer                            28095397
  Capecitabine plus oxaliplatin                     FP2               19                             **77** ^\*^      13/6                              17/2                                                               4/10/5                                    **5/1/11** ^\*^ **-E**                    1 *versus* 3: 0.84 (95% CI, 0.41--1.73)   1 *versus* 3: 0.64 (95% CI, 0.24--1.71)   9/19                                      7/19                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Capecitabine                                      F1                19                             **75** ^\*^      15/4                              18/1                                                               2/10/7                                    **7/4/8** ^\*^ **-E**                     2 *versus* 3: 0.38 (95% CI, 0.14--1.03)   2 *versus* 3: 0.78 (95% CI, 0.34--1.79)   2/19                                      8/19                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Li 2016                                           China             NA                             NA               NA                                5-FU plus leucovorin plus irinotecan                               FI2                                       50                                        Adult                                     NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        NA              Gastric                           NA                        1.23 (95% CI, 0.81--1.88)                     0.87 (95% CI, 0.59--1.27)                     24/50       NA                 NA                 World Chinese Journal of Digestology   28850174
  Capecitabine plus oxaliplatin plus epirubicin     FP3               55                             22/55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Yoon 2016                                         USA               NCT01246960                    II               April 2011---August 2012          5-FU plus oxaliplatin plus leucovorin plus ramucirumab             FP2R                                      84                                        64.5                                      63/21                                     Western                                   80/4                                      NA                                        NA                             NA                      67/17                     40/43/0         **19/26/39** ^\*^ **-E**          Balanced                  1.08 (95% CI, 0.73--1.58)                     0.98 (95% CI, 0.69--1.37)                     38/84       27/82              65/82              Ann Oncol                              27765757
  5-FU plus oxaliplatin plus leucovorin             FP2               84                             60               61/23                             79/5                                                               70/14                                     43/41/0                                   **20/23/41** ^\*^ **-E**                  39/84                                     31/80                                     35/80                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Shah 2016                                         South Korea       NCT01590719                    II               July 2012---May 2013              5-FU plus oxaliplatin plus leucovorin plus onartuzumab             FP2R                                      62                                        58.5                                      40/22                                     Versatile                                 Metastatic                                NA                                        NA                             23/39                   NA                        24/35/0         46/16                             20/31                     1.06 (95% CI, 0.64--1.75)                     1.08 (95% CI, 0.71--1.63)                     26/43       [41/60-2]{.ul}     [10/60-2]{.ul}     Oncologist                             27401892
  5-FU plus oxaliplatin plus leucovorin             FP2               61                             57               36/25                             20/41                                                              24/36/0                                   48/13                                     23/26                                     24/42                                     [29/60-2]{.ul}                            [1/60-2]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                         
  Tebbutt 2016                                      Australia         ACTRN12609000109202            II               April 2010---November 2011        5-FU/capecitabine plus cisplatin plus docetaxel plus panitumumab   FP3R                                      37                                        64                                        33/4                                      Western                                   Metastatic and locally unresectable       26/11                                     13/24                          NA                      Measurable                [34/3]{.ul}     **13/10/15** ^\*^ **-E**          Balanced                  1.02 (95% CI, 0.51--2.05)                     1.08 (95% CI, 0.59--2.01)                     22/37       NA                 26/37              Br J Cancer                            26867157
  5-FU/capecitabine plus cisplatin plus docetaxel   FP3               39                             59               30/9                              23/16                                                              5/34                                      [37/2]{.ul}                               **15/11/13** ^\*^ **-E**                  17/39                                     18/39                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Hironaka 2016                                     Japan             JapicCTI-111635                II               October 2011---December 2012      S-1 plus oxaliplatin plus leucovorin                               FP2                                       47                                        65                                        33/14                                     Eastern                                   40/7                                      NA                                        12/35                          NA                      Measurable                37/10/0         Gastric                           24/23                     1 *versus* 2: 0.76 (95% CI, 0.47--1.24)       1 *versus* 2: 0.52 (95% CI, 0.30--0.88)       31/47       25/47              [28/47-3]{.ul}     Lancet Oncol                           26640036
  S-1 plus leucovorin                               F1                47                             65               37/10                             40/7                                                               11/36                                     37/10/0                                   24/23                                     1 *versus* 3: 0.59 (95% CI, 0.37--0.93)   1 *versus* 3: 0.60 (95% CI, 0.35--1.02)   20/47                                     11/47                                     [10/47-3]{.ul}                                                                                                                                                                                                                                                                                                                                    
  S-1 plus cisplatin                                FP2               48                             65               38/10                             41/7                                                               14/34                                     38/10/0                                   18/30                                     2 *versus* 3: 0.77 (95% CI, 0.49--1.22)   2 *versus* 3: 1.08 (95% CI, 0.67--1.74)   22/48                                     43/48                                     [22/48-3]{.ul}                                                                                                                                                                                                                                                                                                                                    
  Wang 2016                                         China             NCT00811447                    III              November 2008---June 2012         5-FU plus cisplatin plus docetaxel                                 FP3                                       119                                       56.6                                      81/38                                     Eastern                                   89/30                                     NA                                        NA                             46/73                   Measurable                [115/4]{.ul}    99/20                             Balanced                  0.71 (95% CI, 0.52--0.97)                     0.58 (95% CI, 0.42--0.80)                     58/119      [72/119-1]{.ul}    31/119             Gastric Cancer                         25604851
  5-FU plus cisplatin                               FP2               115                            55.5             88/27                             89/26                                                              39/76                                     [108/7]{.ul}                              86/29                                     39/115                                    [11/115-1]{.ul}                           21/115                                                                                                                                                                                                                                                                                                                                                                                                                                
  Du 2015                                           China             NCT02370849                    II               October 2009---February 2012      S-1 plus cisplatin plus nimotuzumab                                FP2R                                      31                                        58                                        17/14                                     Eastern                                   22/9                                      6/25                                      4/27                           8/23                    Measurable                5/26/0          25/6                              Balanced                  1.78 (95% CI, 0.97--3.25)                     2.14 (95% CI, 1.19--3.83)                     17/31       8/31               6/31               Medicine                               26061330
  S-1 plus cisplatin                                FP2               31                             53               26/5                              18/13                                                              3/28                                      5/26                                      9/22                                      7/24/0                                    25/6                                      18/31                                     4/31                                      1/31                                                                                                                                                                                                                                                                                                                                              
  Wu 2015                                           China             **ChiCTR-TRC-13003993** ^\*^   NA               July 2009---June 2011             S-1 plus cisplatin                                                 FP2                                       36                                        64.1                                      25/11                                     Eastern                                   31/5                                      NA                                        NA                             16/20                   Measurable                15/21/0         Gastric                           21/13                     0.81 (95% CI, 0.46--1.43)                     0.76 (95% CI, 0.40--1.46)                     19/36       25/36              30/36              Anticancer Drugs                       25933246
  Cisplatin                                         P1                36                             62.7             23/23                             30/6                                                               18/18                                     16/20/0                                   22/11                                     15/36                                     19/36                                     24/36                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Van Cutsem 2015                                   Belgium           NCT00382720                    II               September 2006---September 2007   5-FU plus oxaliplatin plus leucovorin plus docetaxel               FP3                                       89                                        58                                        61/28                                     Western                                   Metastatic and locally unresectable       63/26                                     17/72                          35/54                   77/12                     [87/2]{.ul}     75/14                             NA                        1 *versus* 2: 0.73 (95% CI, 0.48--1.09)       1 *versus* 2: 0.80 (95% CI, 0.55--1.18)       41/88       [49/88-1]{.ul}     67/88              Ann Oncol                              25416687
  Capecitabine plus oxaliplatin plus docetaxel      FP3               86                             59               64/22                             50/36                                                              17/69                                     40/46                                     80/6                                      [84/2]{.ul}                               75/11                                     1 *versus* 3: 0.51 (95% CI, 0.35--0.76)   1 *versus* 3: 0.43 (95% CI, 0.30--0.63)   21/81                          [50/82-1]{.ul}          73/82                                                                                                                                                                                                                                                                                      
  Oxaliplatin plus docetaxel                        PT2               79                             59               51/28                             55/24                                                              7/72                                      23/56                                     69/10                                     [77/2]{.ul}                               70/9                                      2 *versus* 3: 0.75 (95% CI, 0.51--1.10)   2 *versus* 3: 0.69 (95% CI, 0.49--0.96)   18/78                          [52/78-1]{.ul}          76/78                                                                                                                                                                                                                                                                                      
  Shen 2015                                         China             NCT00887822                    III              March 2009---July 2010            Capecitabine plus cisplatin plus bevacizumab                       FP2R                                      100                                       54.2                                      68/32                                     Eastern                                   95/5                                      39/61                                     NA                             24/76                   81/19                     [95/5]{.ul}     85/15                             Balanced                  1.11 (95% CI, 0.79--1.56)                     0.89 (95% CI, 0.66--1.21)                     33/81       54/100             66/100             Gastric Cancer                         24557418
  Capecitabine plus cisplatin                       FP2               102                            55.5             74/28                             94/8                                                               40/62                                     20/82                                     86/16                                     [97/5]{.ul}                               82/20                                     29/86                                     68/101                                    45/101                                                                                                                                                                                                                                                                                                                                            
  Guimbaud 2014                                     France            NCT00374036                    III              June 2005---May 2008              5-FU plus leucovorin plus irinotecan                               FI2                                       207                                       61.4                                      155/52                                    Western                                   176/31                                    NA                                        NA                             48/159                  Measurable                71/102/27       138/63                            Balanced                  1.01 (95% CI, 0.82--1.24)                     0.99 (95% CI, 0.81--1.21)                     75/198      78/203             108/203            J Clin Oncol                           25287828
  Capecitabine plus cisplatin plus epirubicin       FP3               209                            61.4             154/55                            173/36                                                             54/155                                    61/108/36                                 133/73                                    74/189                                    129/200                                   107/200                                                                                                                                                                                                                                                                                                                                                                                                                               
  Iveson 2014                                       UK                NCT00719550                    II               October 2009---June 2010          Capecitabine plus cisplatin plus epirubicin plus rilotumumab       FP3R                                      82                                        61                                        57/25                                     Western                                   73/9                                      NA                                        NA                             13/69                   76/6                      34/47/1         66/12                             NA                        0.70 (95% CI, 0.45--1.09)                     0.60 (95% CI, 0.45--0.79)                     30/76       56/81              68/81              Lancet Oncol                           24965569
  Capecitabine plus cisplatin plus epirubicin       FP3               39                             60               31/8                              34/5                                                               9/30                                      38/1                                      16/22/1                                   31/4                                      8/38                                      16/39                                     32/39                                                                                                                                                                                                                                                                                                                                                                                       
  Zhang 2014                                        China             NA                             NA               August 2010---September 2012      S-1 plus oxaliplatin plus cetuximab                                FP2R                                      30                                        49                                        37/19                                     Eastern                                   Metastatic and locally unresectable       26/30                                     8/48                           12/44                   Measurable                3/47/6          Gastric                           25/31                     0.74 (95% CI, 0.42--1.30)                     0.67 (95% CI, 0.38--1.18)                     17/30       10/30              3/30               World J Surg Oncol                     24758484
  S-1 plus oxaliplatin                              FP2               26                             11/26            11/26                             5/26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Lu 2014                                           China             NA                             II               January 2009---December 2011      S-1 plus oxaliplatin                                               FP2                                       47                                        63                                        34/13                                     Eastern                                   Metastatic and locally unresectable       18/29                                     19/28                          NA                      Measurable                34/8/5          Gastric                           12/32                     0.60 (95% CI, 0.39--0.94)                     0.57 (95% CI, 0.36--0.91)                     24/47       39/47              27/47              J Chemother                            24621155
  S-1                                               F1                47                             65               33/14                             16/31                                                              20/27                                     33/10/4                                   10/33                                     13/47                                     15/47                                     15/47                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Sugimoto 2014                                     Japan             UMIN000000638                  II               December 2004---November 2007     S-1 plus paclitaxel                                                FT2                                       51                                        62                                        38/13                                     Eastern                                   40/11                                     NA                                        NA                             14/37                   Measurable                39/12/0         Gastric                           33/16                     0.99 (95% CI, 0.64--1.52)                     1.18 (95% CI, 0.79--1.79)                     16/51       3/51               14/51              Anticancer Res                         24511022
  S-1 plus irinotecan                               FI2               51                             64               38/13                             40/11                                                              14/37                                     41/8/2                                    28/22                                     17/51                                     22/48                                     15/48                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Koizumi 2014                                      Japan             NCT00287768                    III              September 2005---September 2008   S-1 plus docetaxel                                                 FT2                                       314                                       65                                        227/87                                    Eastern                                   260/54                                    127/187                                   119/195                        168/146                 242/72                    137/177/0       Gastric and junction              NA                        0.84 (95% CI, 0.71--0.99)                     0.77 (95% CI, 0.65--0.90)                     92/237      208/310            130/310            J Cancer Res Clin Oncol                24366758
  S-1                                               F1                321                            65               229/92                            267/54                                                             135/186                                   131/190                                   163/158                                   249/72                                    147/174/0                                 65/243                                    49/313                                    129/313                                                                                                                                                                                                                                                                                                                                           
  Koizumi 2013                                      Japan             JapicCTI-101327                II               December 2008---February 2012     S-1 plus cisplatin plus orantinib                                  FP2R                                      45                                        62                                        30/15                                     Eastern                                   39/6                                      19/26                                     15/30                          NA                      Measurable                28/17/0         Gastric                           22/23                     0.74 (95% CI, 0.46-1.19)                      1.23 (95% CI, 0.74--2.05)                     28/45       [36/45-2]{.ul}     27/45              Br J Cancer                            24045669
  S-1 plus cisplatin                                FP2               46                             63.5             35/11                             39/7                                                               24/22                                     15/31                                     30/16/0                                   25/20                                     26/46                                     [28/46-2]{.ul}                            14/46                                                                                                                                                                                                                                                                                                                                                                                       
  Shirao 2013                                       Japan             NCT00149201                    III              October 2002---April 2007         5-FU plus leucovorin plus methotrexate                             FM2                                       118                                       59                                        70/48                                     Eastern                                   Metastatic                                NA                                        **118/0** ^\*^                 96/22                   NA                        46/68/4         Gastric                           26/92                     0.94 (95% CI, 0.72--1.22)                     NA                                            NA          81/116             110/116            Jpn J Clin Oncol                       24014884
  5-FU                                              F1                119                            61               66/53                             **119/0** ^\*^                                                     91/28                                     46/69/4                                   25/94                                     13/117                                    77/117                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Richards 2013                                     USA               NCT00517829                    II               December 2007---April 2010        Oxaliplatin plus docetaxel                                         PT2                                       75                                        61.7                                      59/16                                     Western                                   62/13                                     65/10                                     NA                             NA                      Measurable                26/42/7         37/38                             Balanced                  0.94 (95% CI, 0.65--1.36)                     1.00 (95% CI, 0.67--1.49)                     18/68       53/68              25/68              Eur J Cancer                           23747051
  Oxaliplatin plus docetaxel plus cetuximab         PT2R              75                             64               60/15                             55/20                                                              63/12                                     33/33/9                                   34/41                                     27/71                                     58/72                                     46/72                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Waddell 2013                                      UK                NCT00824785                    III              June 2008---October 2011          Capecitabine plus oxaliplatin plus epirubicin plus panitumumab     FP3R                                      278                                       63                                        232/46                                    Western                                   244/34                                    NA                                        NA                             NA                      Measurable                118/144/16      **78/94/106** ^\*^ **-E**         Balanced                  1.37 (95% CI, 1.07--1.76)                     1.22 (95% CI, 0.98--1.52)                     116/254     69/276             264/276            Lancet Oncol                           23594787
  Capecitabine plus oxaliplatin plus epirubicin     FP3               275                            62               226/49                            250/25                                                             117/143/15                                **89/75/111** ^\*^ **-E**                 100/238                                   137/266                                   190/266                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Lordick 2013                                      Germany           EudraCT2007-004219-75          III              June 2008---December 2010         Capecitabine plus cisplatin plus cetuximab                         FP2R                                      455                                       60                                        339/116                                   Versatile                                 439/16                                    NA                                        113/342                        92/363                  Measurable                237/218/0       376/71                            162/76                    1.00 (95% CI, 0.87--1.17)                     1.09 (95% CI, 0.92--1.29)                     136/455     178/446            430/446            Lancet Oncol                           23594786
  Capecitabine plus cisplatin                       FP2               449                            59               334/115                           436/12                                                             116/333                                   90/359                                    228/220/0                                 371/73                                    149/94                                    131/449                                   234/436                                   278/436                                                                                                                                                                                                                                                                                                                                           
  Wang 2013                                         China             NA                             II               January 2008---September 2010     S-1 plus paclitaxel                                                FT2                                       41                                        63                                        32/9                                      Eastern                                   Metastatic and locally unresectable       16/25                                     15/26                          15/26                   Measurable                31/6/4          Gastric                           11/28                     0.55 (95% CI, 0.34--0.90)                     0.60 (95% CI, 0.37--0.97)                     19/41       32/41              36/41              Clin Transl Oncol                      23381898
  S-1                                               F1                41                             61               30/11                             14/27                                                              17/24                                     17/24                                     29/9/3                                    10/30                                     10/41                                     13/41                                     14/41                                                                                                                                                                                                                                                                                                                                                                                       
  Eatock 2013                                       UK                NCT00583674                    II               December 2007---July 2009         Capecitabine plus cisplatin plus trebananib                        FP2R                                      115                                       59                                        85/30                                     Western                                   Metastatic                                NA                                        NA                             7/108                   100/15                    54/60/1         **76/21/18** ^\*^ **-E**          NA                        Median OS time                                0.98 (95% CI, 0.67--1.43)                     35/100      33/114             [44/114-3]{.ul}    Ann Oncol                              23108953
  Capecitabine plus cisplatin                       FP2               56                             62               45/11                             5/51                                                               49/7                                      29/25/2                                   **33/11/12** ^\*^ **-E**                  17/49                                     24/53                                     [22/49-3]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                        
  Al-Batran 2013                                    Germany           NCT00737373                    II               August 2007---October 2008        5-FU plus oxaliplatin plus leucovorin plus docetaxel               FP3                                       72                                        **69** ^\*^                               51/21                                     Western                                   50/22                                     33/39                                     14/58                          18/54                   Measurable                [67/5]{.ul}     45/27                             NA                        0.83 (95% CI, 0.54--1.28)                     0.80 (95% CI, 0.54--1.20)                     35/72       [59/72-2]{.ul}     58/72              Eur J Cancer                           23063354
  5-FU plus oxaliplatin plus leucovorin             FP2               71                             **70** ^\*^      45/26                             49/22                                                              32/39                                     14/57                                     18/53                                     [65/6]{.ul}                               47/24                                     20/71                                     [16/70-2]{.ul}                            46/70                                                                                                                                                                                                                                                                                                                                             
  Andrić 2012                                       Serbia            NA                             NA               2006--2009                        5-FU plus doxorubicin plus mitomycin-C                             FA3                                       25                                        61                                        18/7                                      Western                                   21/4                                      NA                                        NA                             9/16                    NA                        3/22/0          Gastric                           7/18                      1.17 (95% CI, 0.55--2.47)                     NA                                            5/25        3/25               22/25              Srp Arh Celok Lek                      22826983
  5-FU plus cisplatin plus leucovorin               FP2               25                             57               20/5                              20/5                                                               10/15                                     6/19/0                                    6/19                                      6/25                                      0/25                                      7/25                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Roy 2012                                          UK                NA                             II               August 1999---August 2000         Docetaxel plus irinotecan                                          TI2                                       42                                        62                                        35/7                                      Western                                   40/2                                      NA                                        NA                             16/26                   Measurable                7/29/6          27/15                             Balanced                  0.79 (95% CI, 0.52--1.22)                     Median PFS time                               13/42       [35/42-1]{.ul}     [35/42-3]{.ul}     Br J Cancer                            22767144
  5-FU plus docetaxel                               FT2               43                             60               35/8                              40/3                                                               15/28                                     9/22/12                                   19/24                                     11/43                                     [30/43-1]{.ul}                            [18/43-3]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                        
  Mochiki 2012                                      Japan             NA                             II               January 2006---November 2010      S-1 plus paclitaxel                                                FT2                                       42                                        63.3                                      31/11                                     Eastern                                   Metastatic and locally unresectable       14/28                                     11/31                          9/33                    Measurable                38/4/0          Gastric                           16/26                     0.94 (95% CI, 0.55--1.63)                     0.84 (95% CI, 0.50--1.40)                     22/42       8/42               6/42               Br J Cancer                            22617130
  S-1 plus cisplatin                                FP2               41                             63               30/11                             12/29                                                              8/33                                      8/33                                      39/2/0                                    16/25                                     20/41                                     8/41                                      7/41                                                                                                                                                                                                                                                                                                                                                                                        
  Ohtsu 2011                                        Japan             NCT00548548                    III              September 2007---December 2008    Capecitabine plus cisplatin plus bevacizumab                       FP2R                                      387                                       58                                        257/130                                   Versatile                                 367/20                                    130/257                                   NA                             110/277                 311/76                    [365/22]{.ul}   333/54                            NA                        0.87 (95% CI, 0.73--1.04)                     0.80 (95% CI, 0.68--0.93)                     143/311     194/386            165/386            J Clin Oncol                           21844504
  Capecitabine plus cisplatin                       FP2               387                            59               258/129                           378/9                                                              126/261                                   107/280                                   297/90                                    [367/20]{.ul}                             338/49                                    111/297                                   209/381                                   183/381                                                                                                                                                                                                                                                                                                                                           
  Jeung 2011                                        South Korea       NA                             II               July 2005---April 2007            S-1 plus docetaxel                                                 FT2                                       39                                        56                                        31/8                                      Eastern                                   29/10                                     10/29                                     14/25                          12/27                   Measurable                [35/4]{.ul}     Gastric                           Balanced                  0.56 (95% CI, 0.35--0.88)                     0.63 (95% CI, 0.38--1.05)                     18/39       Description        24/39              Cancer                                 21523716
  Cisplatin plus docetaxel                          PT2               41                             60               28/13                             34/7                                                               10/31                                     12/29                                     9/32                                      [35/6]{.ul}                               10/41                                     16/41                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Komatsu 2011                                      Japan             NA                             II               August 2003---March 2005          S-1 plus irinotecan                                                FI2                                       48                                        **70** ^\*^                               34/14                                     Eastern                                   33/15                                     NA                                        NA                             2/46                    Measurable                38/10/0         Gastric                           Balanced                  0.95 (95% CI, 0.64--1.41)                     0.78 (95% CI, 0.54--1.13)                     12/48       21/48              30/48              Anticancer Drugs                       21512394
  S-1                                               F1                47                             **63** ^\*^      37/10                             33/14                                                              4/43                                      35/12/0                                   7/47                                      12/47                                     16/47                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Li 2011                                           China             NA                             II               January 2003---December 2007      5--FU plus cisplatin plus paclitaxel                               FP3                                       50                                        59                                        32/18                                     Eastern                                   28/22                                     NA                                        NA                             NA                      Measurable                [24/26]{.ul}    Gastric                           Balanced                  1.02 (95% CI, 0.63--1.66)                     NA                                            24/50       [4/50-1]{.ul}      [5/50-1]{.ul}      World J Gastroenterol                  21448363
  5-FU plus oxaliplatin plus leucovorin             FP2               44                             58               31/13                             27/17                                                              [21/23]{.ul}                              20/44                                     [4/44-1]{.ul}                             [0/44-1]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Narahara 2011                                     Japan             JapicCTI-050083                III              June 2004---November 2005         S-1 plus irinotecan                                                FI2                                       155                                       63                                        110/45                                    Eastern                                   129/26                                    110/205                                   105/210                        93/62                   Measurable                102/48/5        Gastric                           61/93                     0.89 (95% CI, 0.70--1.15)                     0.86 (95% CI, 0.68--1.08)                     39/94       89/155             98/155             Gastric Cancer                         21340666
  S-1                                               F1                160                            63               127/33                            133/27                                                             93/67                                     109/46/5                                  71/88                                     25/93                                     53/160                                    87/160                                                                                                                                                                                                                                                                                                                                                                                                                                
  Tebbutt 2010                                      Australia         NA                             II               June 2004---May 2006              5-FU plus cisplatin plus docetaxel                                 FP3                                       50                                        60.5                                      42/8                                      Western                                   48/2                                      32/18                                     10/40                          NA                      Measurable                21/28/1         **26/13/11** ^\*^ **-E**          Balanced                  0.84 (95% CI, 0.50--1.39)                     0.73 (95% CI, 0.48--1.13)                     22/47       8/49               [38/49-4]{.ul}     Br J Cancer                            20068567
  Capecitabine plus docetaxel                       FT2               56                             59.1             42/14                             51/5                                                               43/13                                     6/50                                      31/23/2                                   **23/13/20** ^\*^ **-E**                  14/53                                     2/55                                      [23/55-4]{.ul}                                                                                                                                                                                                                                                                                                                                                                              
  Yun 2010                                          South Korea       NCT00743964                    II               April 2008---October 2009         Capecitabine plus cisplatin plus epirubicin                        FP3                                       44                                        55                                        28/16                                     Eastern                                   Metastatic and locally unresectable       12/32                                     26/18                          17/27                   Measurable                [40/1]{.ul}     Gastric                           NA                        NA                                            0.96 (95% CI, 0.58--1.57)                     16/43       31/44              40/44              Eur J Cancer                           20060288
  Capecitabine plus cisplatin                       FP2               45                             58               34/11                             19/26                                                              23/22                                     20/25                                     [41/4]{.ul}                               17/45                                     22/45                                     32/45                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Moehler 2010                                      Germany           NA                             II               October 2003---December 2006      Capecitabine plus irinotecan                                       FI2                                       57                                        61                                        42/15                                     Western                                   Metastatic                                44/13                                     18/39                          20/37                   NA                        0--2            49/7                              NA                        0.77 (95% CI, 0.51--1.17)                     1.14 (95% CI, 0.59--2.21)                     20/53       33/57              50/57              Ann Oncol                              19605504
  Capecitabine plus cisplatin                       FP2               55                             64               36/19                             38/17                                                              20/35                                     14/41                                     38/17                                     21/50                                     48/55                                     54/55                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Ikeda 2009                                        Japan             NA                             II               June 2005---August 2008           S-1 plus docetaxel                                                 FT2                                       24                                        58                                        19/5                                      Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        [21/3]{.ul}     Gastric                           NA                        0.53 (95% CI, 0.28--0.99)                     0.53 (95% CI, 0.28--0.97)                     21/24       [22/24-2]{.ul}     [3/24-3]{.ul}      J Clin Oncol                           10.1200/jco.2009.27.15s.4595
  5-FU plus cisplatin                               FP2               25                             65               23/2                              [23/2]{.ul}                                                        13/25                                     [8/25-2]{.ul}                             [18/25-3]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Boku 2009                                         Japan             NCT00142350                    III              November 2000---January 2006      Cisplatin plus irinotecan                                          PI2                                       236                                       63                                        180/56                                    Eastern                                   190/46                                    NA                                        76/160                         NA                      NA                        151/81/4        Gastric                           102/134                   1 *versus* (2+3): 0.82 (95% CI, 0.68--0.99)   1 *versus* (2+3): 0.73 (95% CI, 0.64--0.83)   68/181      [152/234-1]{.ul}   172/234            Lancet Oncol                           19818685
  S-1                                               F1                234                            64               175/59                            188/46                                                             69/165                                    151/80/3                                  110/124                                   49/174                                    [30/234-1]{.ul}                           94/234                                                                                                                                                                                                                                                                                                                                                                                                                                
  5-FU                                              F1                234                            63.5             176/58                            189/45                                                             87/147                                    152/79/3                                  111/121                                   15/175                                    [36/232-1]{.ul}                           57/232                                                                                                                                                                                                                                                                                                                                                                                                                                
  Ridwelski 2008                                    Germany           NA                             III              NA                                Cisplatin plus docetaxel                                           PT2                                       137                                       62                                        NA                                        Western                                   243/27                                    NA                                        NA                             NA                      NA                        0--2            Gastric                           NA                        1.06 (95% CI, 0.82--1.37)                     1.10 (95% CI, 0.85--1.42)                     32/117      [56/137-1]{.ul}    [27/137-1]{.ul}    J Clin Oncol                           10.1200/jco.2008.26.15_suppl.4512
  5-FU plus cisplatin plus leucovorin               FP2               133                            33/117           [16/133-1]{.ul}                   [38/133-1]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Tesselaar 2008                                    Netherlands       NA                             II               NA                                5-FU plus leucovorin plus paclitaxel                               FT2                                       47                                        NA                                        NA                                        Western                                   Metastatic                                NA                                        NA                             NA                      Measurable                NA              Gastric and junction              NA                        0.79 (95% CI, 0.52--1.20)                     Median PFS time                               21/47       Description        13/47              J Clin Oncol                           10.1200/jco.2008.26.15_suppl.4567
  5-FU plus cisplatin plus leucovorin               FP2               49                             23/49            17/49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Jin 2008                                          China             NCT00202969                    III              July 2005---October 2006          S-1                                                                F1                                        77                                        57                                        56/21                                     Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        [65/12]{.ul}    Gastric                           NA                        (2+3) *versus* 1: 0.55 (95% CI, 0.36--0.83)   Median PFS time                               19/77       6/77               4/77               J Clin Oncol                           10.1200/jco.2008.26.15_suppl.4533
  S-1 plus cisplatin                                FP2               74                             56.5             55/19                             [66/8]{.ul}                                                        28/74                                     26/74                                     17/74                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  5-FU plus cisplatin                               FP2               73                             58               61/12                             [63/10]{.ul}                                                       14/73                                     23/73                                     22/73                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Dank 2008                                         Hungary           NA                             III              June 2000---March 2002            5-FU plus cisplatin                                                FP2                                       163                                       59                                        108/55                                    Western                                   155/8                                     91/72                                     41/122                         66/97                   Measurable                27/134/2        132/31                            42/46                     1.08 (95% CI, 0.86--1.35)                     1.23 (95% CI, 0.97--1.57)                     42/163      [155/166-3]{.ul}   128/166            Ann Oncol                              18558665
  5-FU plus leucovorin plus irinotecan              FI2               170                            58               125/45                            163/7                                                              101/69                                    40/130                                    70/100                                    45/124/1                                  136/34                                    49/60                                     54/170                                    [88/167-3]{.ul}                119/167                                                                                                                                                                                                                                                                                                            
  Koizumi 2008                                      Japan             NCT00150670                    III              March 2002---November 2004        S-1 plus cisplatin                                                 FP2                                       148                                       62                                        108/40                                    Eastern                                   118/30                                    60/88                                     51/97                          53/95                   NA                        106/38/4        Gastric                           45/103                    0.77 (95% CI, 0.61--0.98)                     0.57 (95% CI, 0.44--0.73)                     47/87       127/148            88/148             Lancet Oncol                           18282805
  S-1                                               F1                150                            62               116/34                            119/31                                                             60/90                                     36/114                                    58/92                                     106/39/5                                  60/89                                     33/106                                    27/150                                    24/150                                                                                                                                                                                                                                                                                                                                            
  Park 2008                                         South Korea       NCT00320294                    II               October 2004---November 2006      5-FU plus cisplatin plus leucovorin plus irinotecan                FP3                                       45                                        51                                        30/15                                     Eastern                                   Metastatic and locally unresectable       16/29                                     26/19                          29/16                   Measurable                [38/7]{.ul}     Gastric                           NA                        0.84 (95% CI, 0.38--1.89)                     0.72 (95% CI, 0.44--1.19)                     19/45       27/45              29/45              Ann Oncol                              18083691
  5-FU plus leucovorin plus irinotecan              FI2               46                             55               30/16                             21/25                                                              30/16                                     43/3                                      [35/11]{.ul}                              19/46                                     17/45                                     36/45                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Popov 2008                                        Serbia            NA                             II               August 1998---September 2001      Cisplatin plus doxorubicin plus etoposide                          PA3                                       30                                        57                                        21/9                                      Western                                   27/3                                      18/12                                     10/20                          24/6                    Measurable                3/22/5          21/9                              Balanced                  0.86 (95% CI, 0.32--2.29)                     Median PFS time                               10/30       Cycles             Cycles             Med Oncol                              17972024
  5-FU                                              F1                30                             55               23/7                              22/8                                                               17/13                                     11/19                                     22/8                                      6/19/5                                    19/11                                     3/30                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Roth 2007                                         Switzerland       NA                             II               September 1999---July 2003        5-FU plus cisplatin plus docetaxel                                 FP3                                       41                                        61                                        30/11                                     Western                                   39/2                                      17/24                                     9/32                           13/28                   Measurable                25/16           Gastric                           NA                        (1+2) *versus* 3: 0.96 (95% CI, 0.59--1.54)   (1+2) *versus* 3: 0.79 (95% CI, 0.49--1.27)   15/41       [33/41-1]{.ul}     37/41              J Clin Oncol                           17664469
  5-FU plus cisplatin plus epirubicin               FP3               40                             59               30/10                             33/7                                                               16/24                                     5/35                                      7/33                                      24/16                                     10/40                                     [24/40-1]{.ul}                            23/40                                                                                                                                                                                                                                                                                                                                                                                       
  Cisplatin plus docetaxel                          PT2               38                             58               29/9                              31/7                                                               15/23                                     3/34                                      9/29                                      23/15                                     7/38                                      [29/38-1]{.ul}                            32/38                                                                                                                                                                                                                                                                                                                                                                                       
  Lutz 2007                                         Germany           NA                             II               January 1996---August 1999        5-FU plus cisplatin plus leucovorin                                FP2                                       51                                        62                                        40/11                                     Western                                   45/6                                      NA                                        NA                             23/28                   50/1                      [49/2]{.ul}     Gastric                           22/13                     1 *versus* 2: 0.66 (95% CI, 0.42--1.06)       Median PFS time                               21/46       20/51              32/51              J Clin Oncol                           17577037
  5-FU plus leucovorin                              F1                53                             53               42/11                             47/6                                                               26/27                                     53/0                                      [49/4]{.ul}                               27/10                                     1 *versus* 3: 0.57 (95% CI, 0.35--0.94)   12/48                                     4/53                                      12/48                                                                                                                                                                                                                                                                                                                                             
  5-FU                                              F1                37                             37               30/7                              29/8                                                               22/15                                     36/1                                      [34/3]{.ul}                               20/6                                      2 *versus* 3: 0.83 (95% CI, 0.50--1.37)   2/33                                      5/37                                      12/33                                                                                                                                                                                                                                                                                                                                             
  Van Cutsem 2006                                   Belgium           NA                             III              November 1999---January 2003      5-FU plus cisplatin                                                FP2                                       224                                       55                                        158/66                                    Western                                   217/6                                     NA                                        NA                             71/153                  Measurable                29/192/3        168/56                            45/77                     1.29 (95% CI, 1.02--1.63)                     1.47 (95% CI, 1.19--1.82)                     57/224      [126/224-1]{.ul}   [206/224-3]{.ul}   J Clin Oncol                           17075117
  5-FU plus cisplatin plus docetaxel                FP3               221                            55               159/62                            213/6                                                              68/153                                    28/190/3                                  179/42                                    40/92                                     81/221                                    [181/221-1]{.ul}                          [197/221-3]{.ul}                                                                                                                                                                                                                                                                                                                                                                            
  Ajani 2005                                        USA               NA                             II               June 1998---September 1999        5-FU plus cisplatin plus docetaxel                                 FP3                                       79                                        57                                        61/18                                     Western                                   75/4                                      NA                                        NA                             28/51                   Measurable                7/72/0          50/29                             16/30                     1.19 (95% CI, 0.83--1.69)                     0.80 (95% CI, 0.52--1.22)                     34/79       [66/79-1]{.ul}     [73/79-4]{.ul}     J Clin Oncol                           16110025
  Cisplatin plus docetaxel                          PT2               76                             57               53/23                             72/4                                                               30/46                                     10/65/1                                   56/20                                     20/17                                     20/76                                     [65/76-1]{.ul}                            [39//76-4]{.ul}                                                                                                                                                                                                                                                                                                                                                                             
  Moehler 2005                                      Germany           NA                             II               November 2000---April 2003        5-FU plus leucovorin plus etoposide                                FE2                                       58                                        63                                        49/9                                      Western                                   Metastatic and locally unresectable       42/16                                     11/47                          31/27                   Measurable                8/43/7          42/16                             NA                        1.25 (95% CI, 0.83--1.86)                     1.10 (95% CI, 0.75--1.62)                     14/58       45/58              31/58              Br J Cancer                            15942629
  5-FU plus leucovorin plus irinotecan              FI2               56                             61               40/16                             46/10                                                              10/46                                     29/27                                     4/49/3                                    37/19                                     24/56                                     15/56                                     29/56                                                                                                                                                                                                                                                                                                                                                                                       
  Thuss-Patience 2005                               Germany           NA                             II               NA                                5-FU plus docetaxel                                                FT2                                       45                                        62                                        29/16                                     Western                                   44/1                                      26/19                                     15/30                          NA                      Measurable                14/28/2         31/14                             14/12                     1.02 (95% CI, 0.68--1.54)                     0.96 (95% CI, 0.63--1.48)                     17/45       24/45              23/45              J Clin Oncol                           15659494
  5-FU plus cisplatin plus epirubicin               FP3               45                             63               36/9                              44/1                                                               20/25                                     20/25                                     16/28/1                                   33/12                                     12/19                                     16/45                                     32/45                                     21/45                                                                                                                                                                                                                                                                                                                                             
  Pozzo 2004                                        Italy             NA                             II               January 1999---April 2000         5-FU plus leucovorin plus irinotecan                               FI2                                       74                                        57                                        57/17                                     Western                                   68/6                                      33/41                                     13/61                          28/46                   57/17                     11/63/0         61/12                             22/34                     0.56 (95% CI, 0.39--0.81)                     0.41 (95% CI, 0.26--0.64)                     25/74       33/74              36/74              Ann Oncol                              15550582
  Cisplatin plus irinotecan                         PI2               72                             59               46/26                             69/3                                                               39/33                                     16/56                                     30/42                                     57/15                                     7/65/0                                    49/23                                     27/29                                     18/72                          68/72                   33/72                                                                                                                                                                                                                                                                                      
  Bouché 2004                                       France            NA                             II               January 1999---October 2001       5-FU plus leucovorin plus irinotecan                               FI2                                       45                                        65                                        38/7                                      Western                                   Metastatic                                41/4                                      9/36                           23/22                   Measurable                [35/10]{.ul}    31/14                             Balanced                  1 *versus* 2: 0.93 (95% CI, 0.54--1.58)       1 *versus* 2: 0.84 (95% CI, 0.52--1.35)       18/45       [25/45-2]{.ul}     24/45              J Clin Oncol                           15514373
  5-FU plus cisplatin plus leucovorin               FP2               44                             64               35/9                              42/2                                                               6/44                                      22/22                                     33/11                                     31/13                                     1 *versus* 3: 0.64 (95% CI, 0.38--1.08)   1 *versus* 3: 0.47 (95% CI, 0.29--0.78)   18/45                                     25/45-2                        24/45                                                                                                                                                                                                                                                                                                              
  5-FU plus leucovorin                              F1                45                             64               37/8                              43/2                                                               10/45                                     23/22                                     33/12                                     32/13                                     2 *versus* 3: 0.65 (95% CI, 0.39-1.10)    2 *versus* 3: 0.59 (95% CI, 0.36--0.97)   12/44                                     40/44-2                        16/44                                                                                                                                                                                                                                                                                                              
  Koizumi 2004                                      Japan             NA                             II               July 1991---December 1996         Doxifluridine plus cisplatin plus mitomycin-C                      FP3                                       32                                        58                                        17/15                                     Eastern                                   Metastatic and locally unresectable       10/22                                     8/24                           3/29                    Measurable                5/20/6          Gastric                           Balanced                  0.78 (95% CI, 0.43--1.41)                     NA                                            8/32        14/32              7/32               Anticancer Res                         15330199
  Doxifluridine plus cisplatin                      FP2               29                             58               19/10                             11/18                                                              6/23                                      2/27                                      3/13/9                                    5/29                                      6/29                                      8/29                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Cocconi 2003                                      Italy             NA                             NA               May 1993---November 1999          5-FU plus cisplatin plus leucovorin plus epirubicin                FP3                                       98                                        62                                        67/31                                     Western                                   82/16                                     NA                                        NA                             49/49                   Measurable                0--2            Gastric                           NA                        0.90 (95% CI, 0.77--1.05)                     Median PFS time                               38/98       62/94              50/94              Ann Oncol                              12881389
  5-FU plus doxorubicin plus methotrexate           FA3               97                             62               66/31                             83/14                                                              50/47                                     21/97                                     60/93                                     30/93                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Ohtsu 2003                                        Japan             NA                             III              September 1992---March 1997       UFT plus mitomycin-C                                               FY2                                       70                                        60.5                                      55/15                                     Eastern                                   61/9                                      31/39                                     20/50                          21/49                   Measurable                [63/7]{.ul}     Gastric                           29/39                     1 *versus* 2: 1.53 (95% CI, 1.11--2.11)       1 *versus* 2: 2.16 (95% CI, 1.47--3.17)       6/70        [45/67-2]{.ul}     25/67              J Clin Oncol                           12506170
  5-FU plus cisplatin                               FP2               105                            63               77/28                             90/15                                                              55/50                                     28/77                                     29/76                                     [95/10]{.ul}                              49/52                                     1 *versus* 3: 1.29 (95% CI, 0.93--1.79)   1 *versus* 3: 1.19 (95% CI, 0.84--1.69)   36/105                         [81/102-2]{.ul}         40/102                                                                                                                                                                                                                                                                                     
  5-FU                                              F1                105                            63               75/29                             90/15                                                              49/56                                     23/82                                     27/78                                     [95/10]{.ul}                              47/56                                     2 *versus* 3: 0.84 (95% CI, 0.63--1.11)   2 *versus* 3: 0.63 (95% CI, 0.46--0.86)   12/105                         [15/104-2]{.ul}         26/104                                                                                                                                                                                                                                                                                     
  Tebbutt 2002                                      UK                NA                             III              July 1994---February 2001         5-FU                                                               F1                                        123                                       **72** ^\*^                               94/29                                     Western                                   71/29                                     NA                                        NA                             NA                      NA                        11/72/37        **55/33/29** ^\*^ **-E**          Balanced                  0.96 (95% CI, 0.75--1.22)                     1.09 (95% CI, 0.86--1.38)                     19/118      17/123             59/123             Ann Oncol                              12377644
  5-FU plus mitomycin-C                             FY2               127                            **72** ^\*^      95/32                             73/30                                                              9/70/44                                   **69/30/27** ^\*^ **-E**                  23/121                                    27/127                                    56/127                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Kim 2001                                          South Korea       NA                             III              March 1997---April 2000           5-FU plus cisplatin plus epirubicin                                FP3                                       61                                        55                                        45/15                                     Eastern                                   57/3                                      32/29                                     NA                             NA                      Measurable                [55/6]{.ul}     Gastric                           NA                        0.83 (95% CI, 0.42--1.61)                     Median PFS time                               22/61       [23/61-2]{.ul}     [32/61-3]{.ul}     Eur J Cancer                           10.1016/S0959-8049(01)81651-8
  5-FU plus cisplatin                               FP2               60                             56.5             42/18                             57/3                                                               28/32                                     [53/7]{.ul}                               20/60                                     [10/60-2]{.ul}                            [10/60-3]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Vanhoefer 2000                                    Germany           NA                             III              July 1991---April 1995            5-FU plus leucovorin plus etoposide                                FE2                                       132                                       59                                        90/38                                     Western                                   110/22                                    NA                                        NA                             78/54                   122/10                    54/66/12        Gastric                           57/45                     1 *versus* 3: 0.95 (95% CI, 0.74--1.24)       1 *versus* 3: 1.02 (95% CI, 0.79--1.32)       7/79        68/129             62/129             J Clin Oncol                           10894863
  5-FU plus cisplatin                               FP2               134                            57               91/41                             113/21                                                             73/61                                     125/9                                     43/71/20                                  65/43                                     2 *versus* 3: 0.98 (95% CI, 0.86--1.12)   2 *versus* 3: 0.94 (95% CI, 0.83--1.07)   16/81                                     73/127                         84/127                                                                                                                                                                                                                                                                                                             
  5-FU plus doxorubicin plus methotrexate           FA3               133                            58               96/34                             111/22                                                             67/66                                     122/11                                    36/81/16                                  59/47                                                                                                                         10/85                                     89/122                         57/122                                                                                                                                                                                                                                                                                                             
  Roth 1999                                         Croatia           NA                             NA               NA                                5-FU plus cisplatin plus epirubicin                                FP3                                       54                                        55                                        NA                                        Western                                   74/36                                     NA                                        NA                             NA                      Measurable                [57/53]{.ul}    Gastric                           NA                        0.74 (95% CI, 0.55--0.99)                     NA                                            16/56       Description        Description        Tumori                                 10587023
  5-FU plus epirubicin                              FA2               56                             23/54                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Waters 1999                                       UK                NA                             NA               July 1992---June 1995             5-FU plus doxorubicin plus methotrexate                            FA3                                       130                                       60                                        110/20                                    Western                                   79/51                                     NA                                        NA                             48/82                   NA                        [97/32]{.ul}    **73/33/24** ^\*^ **-E**          Balanced                  1.52 (95% CI, 1.19--1.95)                     1.79 (95% CI, 1.40--2.29)                     24/116      [126/130-2]{.ul}   111/130            Br J Cancer                            10390007
  5-FU plus cisplatin plus epirubicin               FP3               126                            59               99/27                             79/47                                                              51/75                                     [96/30]{.ul}                              **72/27/27** ^\*^ **-E**                  56/121                                    [60/126-2]{.ul}                           122/126                                                                                                                                                                                                                                                                                                                                                                                                                               
  Içli 1998                                         Turkey            NA                             III              1994--1997                        5-FU plus cisplatin plus epirubicin                                FP3                                       67                                        52.7                                      40/27                                     Western                                   53/14                                     NA                                        NA                             NA                      Measurable                8/38/21         Gastric                           NA                        1.23 (95% CI, 0.76--1.98)                     1.07 (95% CI, 0.58--1.96)                     9/59        4/67               15/67              Cancer                                 9874451
  Cisplatin plus epirubicin plus etoposide          PA3               64                             52.7             44/20                             53/11                                                              6/36/22                                   12/59                                     6/64                                      10/64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Yamamura 1998                                     Japan             NA                             NA               NA                                5-FU plus pirarubicin plus methotrexate                            FA3                                       37                                        NA                                        NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        NA              Gastric                           NA                        0.88 (95% CI, 0.55--1.41)                     NA                                            NA          Description        Description        Gan To Kagaku Ryoho                    9725047
  5-FU                                              F1                34                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Barone 1998                                       Italy             NA                             II               January 1993---December 1995      Cisplatin plus epirubicin plus etoposide                           PA3                                       36                                        57.3                                      26/10                                     Western                                   Metastatic and locally unresectable       19/17                                     17/19                          22/14                   Measurable                [28/8]{.ul}     Gastric                           NA                        0.89 (95% CI, 0.55--1.42)                     Median PFS time                               6/33        Cycles             Cycles             Cancer                                 9554521
  5-FU plus leucovorin                              F1                36                             59               24/12                             17/19                                                              18/18                                     20/16                                     [28/8]{.ul}                               7/32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Scheithauer 1996                                  Austria           NA                             NA               NA                                5-FU plus leucovorin plus doxorubicin                              FA2                                       52                                        NA                                        NA                                        Western                                   65/38                                     NA                                        NA                             NA                      NA                        [73/30]{.ul}    Gastric                           NA                        0.49 (95% CI, 0.33--0.74)                     0.31 (95% CI, 0.21--0.45)                     NA          NA                 NA                 Ann Hematol                            28850174
  Supportive care                                   S                 51                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Colucci 1995                                      Italy             NA                             NA               NA                                5-FU plus leucovorin plus etoposide                                FE2                                       31                                        56                                        20/11                                     Western                                   Metastatic and locally unresectable       14/17                                     1/30                           18/13                   Measurable                0--2            Gastric                           NA                        0.70 (95% CI, 0.42--1.16)                     NA                                            13/31       4/31               15/31              Am J Clin Oncol                        8526196
  5-FU plus leucovorin                              F1                31                             58               20/11                             17/14                                                              1/30                                      20/11                                     9/31                                      2/31                                      4/31                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Pyrhönen 1995                                     Finland           NA                             III              July 1986---June 1992             5-FU plus leucovorin plus epirubicin                               FA2                                       21                                        58                                        15/6                                      Western                                   15/6                                      8/13                                      4/17                           15/6                    Measurable                4/15/2          Gastric                           NA                        0.35 (95% CI, 0.15--0.81)                     0.29 (95% CI, 0.13--0.65)                     6/21        12/21              13/21              Br J Cancer                            7533517
  Supportive care                                   S                 20                             58               10/10                             14/6                                                               8/12                                      2/18                                      16/4                                      3/15/2                                    0/20                                      0/20                                      0/20                                                                                                                                                                                                                                                                                                                                                                                        
  Coombes 1994                                      UK                NA                             NA               August 1985---September 1988      Epirubicin                                                         A1                                        36                                        59.9                                      27/9                                      Western                                   34/2                                      18/18                                     8/28                           NA                      Measurable                0--2            Gastric                           NA                        1.09 (95% CI, 0.56--2.12)                     NA                                            3/36        3/36               25/36              Ann Oncol                              8172789
  5-FU                                              F1                33                             55.6             24/9                              31/2                                                               15/18                                     5/28                                      2/33                                      4/33                                      9/33                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Cocconi 1994                                      Italy             NA                             III              August 1988---November 1991       5-FU plus cisplatin plus leucovorin plus epirubicin                FP3                                       85                                        62                                        60/25                                     Western                                   78/7                                      NA                                        NA                             31/21                   46/6                      0--3            Gastric                           NA                        0.69 (95% CI, 0.51--0.93)                     Median PFS time                               37/85       13/85              28/85              J Clin Oncol                           7989945
  5-FU plus doxorubicin plus mitomycin-C            FA3               52                             65               42/10                             43/9                                                               54/31                                     76/9                                      8/52                                      1/52                                      8/52                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Loehrer 1994                                      USA               NA                             NA               January 1985---January 1987       5-FU                                                               F1                                        69                                        59                                        NA                                        Western                                   44/25                                     34/35                                     16/53                          NA                      47/22                     12/34/22        Gastric                           NA                        1 *versus* 2: 0.75 (95% CI, 0.43--1.31)       1 *versus* 2: 0.42 (95% CI, 0.21--0.83)       5/40        21/69              48/69              Invest New Drugs                       7960608
  Epirubicin                                        A1                26                             57               15/11                             11/15                                                              5/21                                      17/9                                      7/11/5                                    1 *versus* 3: 0.98 (95% CI, 0.67--1.44)   1 *versus* 3: 1.02 (95% CI, 0.69--1.53)   1/16                                      6/26                                      18/26                                                                                                                                                                                                                                                                                                                                             
  5-FU plus epirubicin                              FA2               70                             62               45/25                             35/35                                                              16/54                                     50/20                                     16/31/14                                  2 *versus* 3: 1.25 (95% CI, 0.73--2.14)   2 *versus* 3: 4.55 (95% CI, 2.40--8.65)   4/33                                      48/70                                     68/70                                                                                                                                                                                                                                                                                                                                             
  Cullinan 1994                                     USA               NA                             NA               February 1984---March 1992        5-FU plus doxorubicin plus Me-CCNU plus triazinate                 FA4                                       79                                        60                                        53/26                                     Western                                   Metastatic and locally unresectable       NA                                        NA                             31/48                   16/63                     [55/24]{.ul}    Gastric                           Balanced                  1 *versus* 4: 0.95 (95% CI, 0.65--1.38)       1 *versus* 4: 0.65 (95% CI, 0.46--0.94)       NA          47/79              47/79              J Clin Oncol                           8113849
  5-FU plus cisplatin plus doxorubicin              FP3               51                             61               40/11                             21/30                                                              6/45                                      [35/16]{.ul}                              2 *versus* 4: 1.17 (95% CI, 0.77--1.76)   2 *versus* 4: 0.84 (95% CI, 0.57--1.26)   29/51                                     30/51                                                                                                                                                                                                                                                                                                                                                                                                                                 
  5-FU plus doxorubicin plus Me-CCNU                FA3               53                             63               43/10                             18/35                                                              6/47                                      [36/17]{.ul}                              3 *versus* 4: 0.97 (95% CI, 0.62--1.52)   3 *versus* 4: 0.90 (95% CI, 0.60--1.34)   34/53                                     16/53                                                                                                                                                                                                                                                                                                                                                                                                                                 
  5-FU                                              F1                69                             63               52/17                             24/45                                                              14/55                                     [50/19]{.ul}                                                                                                                  28/69                                     12/69                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Murad 1993                                        Brazil            NA                             II               1988--1991                        5-FU plus doxorubicin plus methotrexate                            FA3                                       30                                        58                                        20/10                                     Versatile                                 21/9                                      NA                                        NA                             13/17                   Measurable                5/16/9          Gastric                           NA                        0.33 (95% CI, 0.17--0.64)                     NA                                            15/30       2/30               7/30               Cancer                                 8508427
  Supportive care                                   S                 10                             57               7/3                               6/4                                                                3/7                                       3/4/3                                     0/10                                      0/10                                      0/10                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Kim 1993                                          South Korea       NA                             III              August 1986---June 1990           5-FU plus doxorubicin plus mitomycin-C                             FA3                                       98                                        54                                        68/30                                     Eastern                                   Metastatic and locally unresectable       34/64                                     NA                             22/76                   57/41                     [75/23]{.ul}    Gastric                           22/48                     1 *versus* 2: 1.36 (95% CI, 0.99--1.86)       Median PFS time                               14/57       Cycles             [93/98-2]{.ul}     Cancer                                 8508349
  5-FU plus cisplatin                               FP2               103                            51               71/32                             38/65                                                              15/88                                     55/48                                     [83/20]{.ul}                              30/52                                     1 *versus* 3: 1.21 (95% CI, 0.88--1.67)   28/55                                     [101/103-2]{.ul}                                                                                                                                                                                                                                                                                                                                                                            
  5-FU                                              F1                94                             54               66/28                             33/61                                                              10/84                                     54/50                                     [76/18]{.ul}                              26/45                                     2 *versus* 3: 0.84 (95% CI, 0.61--1.17)   14/54                                     [44/94-2]{.ul}                                                                                                                                                                                                                                                                                                                                                                              
  KRGGC 1992                                        South Korea       NA                             NA               NA                                5-FU plus cisplatin plus epirubicin                                FP3                                       25                                        NA                                        NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        NA              Gastric                           NA                        0.57 (95% CI, 0.27--1.20)                     NA                                            5/21        Description        Description        Anticancer Res                         1295444
  5-FU plus cisplatin                               FP2               22                             6/22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Kelsen 1992                                       USA               NA                             NA               June 1988---October 1990          5-FU plus leucovorin plus doxorubicin plus methotrexate            FA3                                       30                                        56                                        22/8                                      Western                                   19/11                                     16/14                                     2/28                           NA                      Measurable                0--2            Gastric and junction              NA                        0.79 (95% CI, 0.42--1.46)                     NA                                            10/30       Description        Description        J Clin Oncol                           1548519
  Cisplatin plus doxorubicin plus etoposide         PA3               30                             57               24/6                              21/9                                                               16/14                                     3/27                                      6/30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Kikuchi 1990                                      Japan             NA                             NA               NA                                5-FU plus cisplatin plus doxorubicin                               FP3                                       32                                        NA                                        NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        NA              Gastric                           NA                        0.58 (95% CI, 0.36--0.95)                     NA                                            6/18        Description        Description        Gan To Kagaku Ryoho                    2181941
  5-FU plus doxorubicin                             FA2               33                             0/19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  GITSG 1988                                        USA               NA                             III              November 1981---July 1985         5-FU plus cisplatin plus doxorubicin                               FP3                                       85                                        18--75                                    63/22                                     Western                                   Metastatic                                41/44                                     NA                             NA                      31/54                     [58/27]{.ul}    Gastric                           NA                        1 *versus* 2: 0.98 (95% CI, 0.67--1.45)       NA                                            6/30        64/85              33/85              J Natl Cancer Inst                     2900901
  5-FU plus doxorubicin plus triazinate             FA3               81                             60/21            32/49                             30/51                                                              [53/28]{.ul}                              1 *versus* 3: 0.71 (95% CI, 0.49--1.02)   6/31                                      23/81                                     25/81                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  5-FU plus doxorubicin plus Me-CCNU                FA3               81                             51/30            40/41                             33/48                                                              [51/30]{.ul}                              2 *versus* 3: 0.71 (95% CI, 0.49--1.03)   5/33                                      61/81                                     12/81                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Lacave 1987                                       Spain             NA                             III              April 1979---June 1983            5-FU plus doxorubicin plus Me-CCNU                                 FA3                                       85                                        58                                        55/30                                     Western                                   65/20                                     32/53                                     43/42                          60/25                   28/57                     0--3            Gastric                           NA                        0.82 (95% CI, 0.59--1.14)                     NA                                            5/28        Description        Description        J Clin Oncol                           3305795
  5-FU plus doxorubicin                             FA2               88                             59               65/23                             74/14                                                              50/38                                     48/40                                     63/25                                     29/59                                     3/29                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Levi 1986                                         Australia         NA                             NA               NA                                5-FU plus doxorubicin plus BCNU                                    FA3                                       94                                        61                                        68/26                                     Western                                   Metastatic and locally unresectable       28/66                                     22/72                          42/52                   75/19                     [68/18]{.ul}    Gastric                           Balanced                  0.58 (95% CI, 0.43--0.77)                     0.62 (95% CI, 0.30--1.28)                     30/75       13/94              10/94              J Clin Oncol                           3528404
  Doxorubicin                                       A1                93                             59               68/25                             26/67                                                              17/76                                     41/52                                     70/24                                     [63/23]{.ul}                              9/70                                      5/93                                      14/93                                                                                                                                                                                                                                                                                                                                                                                       
  De Lisi 1986                                      Italy             NA                             III              NA                                5-FU plus doxorubicin plus mitomycin-C plus BCNU                   FA4                                       42                                        64                                        NA                                        Western                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                        NA              Gastric                           NA                        1.16 (95% CI, 0.26--5.15)                     NA                                            9/41        Description        Description        Cancer Treat Rep                       3516397
  5-FU                                              F1                42                             6/41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Cullinan 1985                                     USA               NA                             NA               NA                                5-FU                                                               F1                                        51                                        18--75                                    36/15                                     Western                                   32/19                                     NA                                        NA                             NA                      11/40                     [37/14]{.ul}    Gastric                           NA                        1 *versus* 2: 0.96 (95% CI, 0.60--1.52)       1 *versus* 2: 0.99 (95% CI, 0.62--1.59)       2/11        Description        Description        JAMA                                   2579257
  5-FU plus doxorubicin                             FA2               49                             37/12            31/18                             10/39                                                              [33/16]{.ul}                              1 *versus* 3: 0.91 (95% CI, 0.56--1.48)   1 *versus* 3: 1.17 (95% CI, 0.70--1.96)   3/11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  5-FU plus doxorubicin plus mitomycin-C            FA3               51                             39/12            31/20                             13/38                                                              [32/19]{.ul}                              2 *versus* 3: 0.99 (95% CI, 0.64--1.53)   2 *versus* 3: 1.30 (95% CI, 0.82--2.06)   5/13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Douglass 1984                                     USA               NA                             NA               NA                                5-FU plus doxorubicin plus Me-CCNU                                 FA3                                       39                                        62                                        31/8                                      Western                                   Metastatic and locally unresectable       NA                                        NA                             NA                      Measurable                9/21/6          Gastric                           Balanced                  1 *versus* 2: 1.61 (95% CI, 0.88--2.92)       NA                                            11/39       14/39              3/39               J Clin Oncol                           6439836
  5--FU plus doxorubicin plus mitomycin--C          FA3               46                             61               35/11                             11/19/13                                                           1 *versus* 3: 0.72 (95% CI, 0.39--1.35)   18/46                                     14/46                                     1/46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  5-FU plus Me-CCNU                                 FU2               44                             58               35/9                              9/23/10                                                            1 *versus* 4: 0.94 (95% CI, 0.54--1.64)   6/44                                      13/44                                     4/44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Doxorubicin plus mitomycin-C                      AY2               46                             59.5             33/13                             8/20/14                                                            13/46                                     13/46                                     6/46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  O'Connel 1984                                     USA               NA                             NA               December 1978---March 1981        5-FU plus doxorubicin plus Me-CCNU                                 FA3                                       76                                        62                                        53/23                                     Western                                   60/16                                     29/41                                     NA                             NA                      16/44                     18/38/20        Gastric                           Balanced                  1 *versus* 2: 0.89 (95% CI, 0.58--1.37)       NA                                            4/16        60/76              11/76              Cancer                                 6418371
  5-FU plus doxorubicin plus mitomycin-C            FA3               78                             62               52/26                             62/16                                                              23/46                                     18/44                                     17/38/23                                  1 *versus* 3: 0.82 (95% CI, 0.54--1.26)   3/18                                      40/78                                     7/78                                                                                                                                                                                                                                                                                                                                                                                        
  5-FU plus doxorubicin                             FA2               78                             60               57/21                             60/18                                                              21/54                                     19/41                                     16/40/22                                  2 *versus* 3: 0.92 (95% CI, 0.62--1.39)   1/19                                      32/78                                     7/78                                                                                                                                                                                                                                                                                                                                                                                        
  Friedman 1983                                     USA               NA                             III              December 1977-- December 1980     Tegafur plus doxorubicin plus BCNU                                 FA3                                       36                                        18--75                                    24/12                                     Western                                   27/9                                      NA                                        NA                             15/21                   22/14                     0--3            Gastric                           NA                        1.03 (95% CI, 0.64--1.66)                     NA                                            3/22        9/36               4/36               Cancer                                 6414682
  5-FU plus doxorubicin                             FA2               38                             22/16            28/10                             19/19                                                              19/19                                     1/19                                      14/38                                     2/38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Tegafur plus doxorubicin plus mitomycin-C         FA3               34                             22/12            Eastern                           28/6                                                               8/29                                      12/22                                     0.79 (95% CI, 0.39--1.59)                 NA                                        1/12                                      10/34                                     0/34                                                                                                                                                                                                                                                                                                                                                                                        
  5-FU plus doxorubicin                             FA2               34                             21/13            27/7                              5/26                                                               22/12                                     3/22                                      5/34                                      1/34                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  O'Connel 1982                                     USA               NA                             NA               NA                                5-FU plus doxorubicin plus mitomycin-C                             FA3                                       43                                        62                                        29/14                                     Western                                   Metastatic and locally unresectable       NA                                        NA                             NA                      12/31                     18/25           Gastric                           NA                        1 *versus* 2: 1.13 (95% CI, 0.57--2.25)       Median PFS time                               3/12        7/43               Description        Cancer                                 7037163
  5-FU plus doxorubicin plus Me-CCNU                FA3               34                             59               25/9                              10/24                                                              21/13                                     1 *versus* 3: 0.69 (95% CI, 0.38--1.26)   3/10                                      7/34                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  5-FU plus Me-CCNU plus razoxane                   FU3               46                             62               32/14                             19/27                                                              17/29                                     1 *versus* 4: 0.87 (95% CI, 0.46--1.64)   4/19                                      15/46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  5-FU plus Me-CCNU                                 FU2               58                             64               34/24                             18/40                                                              29/29                                                                               1/18                                      17/58                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Buroker 1979                                      USA               NA                             II               March 1975-- March 1977           5-FU plus mitomycin-C                                              FY2                                       80                                        18--75                                    NA                                        Western                                   Metastatic and locally unresectable       28/52                                     NA                             NA                      43/37                     NA              Gastric                           NA                        0.86 (95% CI, 0.60--1.21)                     NA                                            6/43        Cycles             Cycles             Cancer                                 387204
  5-FU plus Me-CCNU                                 FU2               88                             40/48            55/33                             5/54                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

**Notes:** Items that may produce significant heterogeneity are emphasized with bold-type letters and asterisks. Underlined data in PS (0/1/2) indicates that the numbers should be interpreted as PS (0 and 1) *versus* PS (2). The additional letter 'E' in certain items of 'Location (G/J)' suggested that there were additional esophageal cancer cases in addition to gastric and gastroesophageal junction cancer cases. The word 'Balanced' in 'Histological type (I/D)' indicated that although there was no description about the ratio of intestinal and diffused types, there were other classifications of histological grades and both arms were well balanced. In multi-arm studies, for example, '1 *versus* 2' in survival data referred to the hazard ratio of first regimen *versus* the second regimen. In terms of adverse events, since the number of events sometimes surpassed the total number of patients, therefore in those situations we only calculated the most significant types of adverse event in each category. The numbers of selected types of adverse events were identified inside the cells and underlined. Moreover, the words 'Description' or 'Cycles' inside adverse events suggested that there was no quantitative data or the quantitative data was calculated by chemotherapeutic cycles rather than patient-level comparison, respectively. Regarding 'PMID', those studies without a specific PubMed ID were either replaced by a DOI number or the PubMed ID of previous systematic reviews carrying relevant information. Unless clarified, the hazard ratios were the results of upper arm *versus* lower arm in each trial.

E/T, events/total patients; G/J, gastric/junction; hAE, hematological adverse events; HR, hazard ratio; I/D, intestinal/diffused; M/F, male/female; NA, not available; non-hAE, nonhematological adverse events; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; P/T, responsive patients/total patients;

**Nodes:** 1, monotherapy; 2, doublet; 3, triplet; A, anthracycline; E, etoposide; F, fluoropyrimidine; I, irinotecan; M, methotrexate; P, platinum; R, targeted medication; S, best supportive care; T, taxane; Y, mitomycin-C; U, nitrosourea. Details of the rationale for organizing the nodes are described in main text.

First, all included studies were randomized controlled trials that minimized the methodological heterogeneity induced by different study designs. Second, patients in most studies shared similar and comparable baseline characteristics that guaranteed the treatment effects not to be artificially biased owing to unbalanced confounding information. For example, in most studies, patients were PS \< 2, metastatic, measurable, and gastric cancer cases, without specific inclination of histological types. Other potential difference in baseline features were either unable to alter the results (such as small amount of esophagogastric junction cases) or addressed by sensitivity analysis ([Table 1](#table1-1758835919877726){ref-type="table"}). All these had justified the transitivity and performance of our network meta-analysis.

General analysis: risk of bias {#section18-1758835919877726}
------------------------------

Overall, the included studies had low risk of bias since nearly half of the assessment parameters were scored as low risk of bias (45%), while unclear risk (39%) or high risk of bias (16%) took up relatively small proportions ([Figure 2](#fig2-1758835919877726){ref-type="fig"}). None of the eligible studies were at high risk of bias concerning methodological design ([Supplementary Table 2](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

![Risk of bias assessment in general analysis.](10.1177_1758835919877726-fig2){#fig2-1758835919877726}

Specifically, 31% and 48% of the studies were evaluated as low risk of bias concerning random sequence generation and allocation concealment, respectively, while no high risk of bias was reported in these two key domains. Largely due to the open-label design, 90% of the included trials were scored as high risk of bias in terms of blinding or participants and personnel. Meanwhile, since there was a lack of details on whether the response evaluation was independent enough, more than half of the studies (63%) were evaluated as unclear risk of bias regarding blinding of outcome assessment. In addition, because most of the studies were analyzed based on the intent-to-treat population as well as having reported enough endpoints, 79% and 72% of the eligible trials had low risk of bias in terms of incomplete outcome data and selective reporting, respectively. Moreover, since the majority of studies were completely performed without early termination and also described adequate baseline details, nearly half of the studies (48%) were appraised as low risk of bias with respect to other source of bias ([Figure 2](#fig2-1758835919877726){ref-type="fig"}).

General analysis: primary endpoint (OS) {#section19-1758835919877726}
---------------------------------------

### Network geometry {#section20-1758835919877726}

There were a total of 91 randomized controlled trials merged into the quantitative analysis, with 17,529 participants and 24 nodes of therapeutic regimen ([Figure 3](#fig3-1758835919877726){ref-type="fig"} and [Table 1](#table1-1758835919877726){ref-type="table"}).

![Network structure plot of overall survival in general analysis.\
**Note:** The size of nodes implicates the number of studies of each regimen while the width of the lines is proportional to the amount of mutual direct comparisons.\
**Nodes:** 1, monotherapy; 2, doublet; 3, triplet; A, anthracycline; E, etoposide; F, fluoropyrimidine; I, irinotecan; M, methotrexate; P, platinum; R, targeted medication; S, best supportive care; T, taxane; U, nitrosourea; Y, mitomycin-C.](10.1177_1758835919877726-fig3){#fig3-1758835919877726}

### Consistency and statistical heterogeneity {#section21-1758835919877726}

In addition to the value of *Q* statistic (*Q* inconsistency: *p* = 0.08), the effect size and CI between direct and indirect results were highly overlapped ([Supplementary Table 3](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)), both of which suggested that results inside the entire network were consistent. In terms of statistical heterogeneity, both *I*^2^ statistic (*I*^2^ = 15.00%) and *Q* statistic (*Q* heterogeneity: *p* = 0.29) implied that there was no significant heterogeneity across the network.

### Publication bias {#section22-1758835919877726}

There was no publication bias among the included studies owing to the symmetrical distribution of effect sizes inside the funnel plot ([Supplementary Figure 1](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

### Network calculation {#section23-1758835919877726}

Based on P-score ranking of the network meta-analysis, 'fluoropyrimidine plus platinum-based triplet' (network HR 95% CI: 0.91 (0.83--0.99), P-score = 0.903) was the best ranking regimen, displaying statistical superiority against common comparator 'fluoropyrimidine plus platinum doublet' (*p* = 0.04). The network forest plot and league table are shown in [Figures 4](#fig4-1758835919877726){ref-type="fig"} and [5](#fig5-1758835919877726){ref-type="fig"}, respectively. These results were also consistent with pairwise meta-analysis, where 'fluoropyrimidine plus platinum-based triplet' was better than 'fluoropyrimidine plus platinum doublet' (random HR 95% CI: 0.86 (0.75--0.98), *p* = 0.03; [Supplementary Table 3](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

![Network forest plot of overall survival in general analysis.](10.1177_1758835919877726-fig4){#fig4-1758835919877726}

![Network league table of overall survival in general analysis.\
**Note:** Treatments are hierarchically ranked according to their P-score. The higher the position in the table a regimen is located, the better survival benefits it could offer. Values situated at the intersection of a specific column and row are the network effect sizes (HR and 95% CI) of row-defining regimen *versus* column-defining regimen.](10.1177_1758835919877726-fig5){#fig5-1758835919877726}

### Sensitivity analysis {#section24-1758835919877726}

After changing to a fixed-effects model (network HR 95% CI: 0.91 (0.84--0.98), P-score = 0.916) or removing clinically heterogeneous studies (network HR 95% CI: 0.90 (0.82--0.99), P-score = 0.903), 'fluoropyrimidine plus platinum-based triplet' remained as the top node with statistical advantage against 'fluoropyrimidine plus platinum doublet' (figures not shown).

General analysis: secondary endpoint {#section25-1758835919877726}
------------------------------------

### PFS {#section26-1758835919877726}

A total of 63 studies were included in the network calculation. 'Fluoropyrimidine plus platinum-based triplet plus targeted medication' became the best regimen in the entire hierarchy (network HR 95% CI: 0.75 (0.54--1.04), P-score = 0.919), closely followed by 'fluoropyrimidine plus platinum-based triplet' (network HR 95% CI: 0.83 (0.71--0.96), P-score = 0.881). However, only 'fluoropyrimidine plus platinum-based triplet' had shown statistical superiority against 'fluoropyrimidine plus platinum doublet' (*p* = 0.01) ([Supplementary Figure 2](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

### ORR {#section27-1758835919877726}

A total of 89 studies were eligible and merged into the hierarchical comparisons. 'Fluoropyrimidine plus platinum-based triplet plus targeted medication' (network RR 95% CI: 1.48 (1.11--1.98), P-score = 0.964) and 'fluoropyrimidine plus platinum-based triplet' (network RR 95% CI: 1.20 (1.06--1.36), P-score = 0.857) again ranked as the top two nodes in the entire hierarchy, both of which demonstrated statistical advantage against common comparator 'fluoropyrimidine plus platinum doublet' (FP3R: *p* = 0.008; FP3: *p* = 0.004) ([Supplementary Figure 3](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

### Hematological adverse events {#section28-1758835919877726}

A total of 74 studies were included in the network meta-analysis. 'Best supportive care' was certainly the most tolerable node in the rankings (network RR 95% CI: 0.16 (0.02--1.28), P-score = 0.952). Meanwhile, based on the hierarchical data, both 'fluoropyrimidine plus platinum-based triplet plus targeted medication' (network RR 95% CI: 1.31 (0.75--2.29), P-score = 0.414) and 'fluoropyrimidine plus platinum-based triplet' (network RR 95% CI: 1.55 (1.25--1.90), P-score = 0.272) had worse rankings than 'fluoropyrimidine plus platinum doublet' while the difference between 'fluoropyrimidine plus platinum-based triplet' and 'fluoropyrimidine plus platinum doublet' was statistically meaningful (*p* = 0.0001) ([Supplementary Figure 4](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

### Nonhematological adverse events {#section29-1758835919877726}

A total of 78 studies were included in the network meta-analysis. Undoubtedly, 'Best supportive care' was the most tolerable node concerning nonhematological adverse events (network RR 95% CI: 0.07 (0.01--0.50), P-score = 0.993). Both 'fluoropyrimidine plus platinum-based triplet' (network RR 95% CI: 1.15 (0.99--1.34), P-score = 0.315) and 'fluoropyrimidine plus platinum-based triplet plus targeted medication' (network RR 95% CI: 1.44 (1.02--2.03), P-score = 0.176) displayed lower rankings than 'fluoropyrimidine plus platinum doublet' while the difference between 'fluoropyrimidine plus platinum-based triplet plus targeted medication' and 'fluoropyrimidine plus platinum doublet' was statistical meaningful (*p* = 0.04) ([Supplementary Figure 5](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

Additional analysis {#section30-1758835919877726}
-------------------

Although the results from general analysis seemed to be very consistent, however, since there were several subtypes of medications included in fluoropyrimidines and platinum, we decided to perform an additional analysis by only including studies with pairwise comparisons between fluoropyrimidine plus platinum-based regimens. This not only helped to lower the heterogeneity across the network but also enhanced the clinical specificity and availability. Overall 39 randomized controlled trials were eligible for additional analysis, containing a total of 10,959 patients. '5-FU plus cisplatin' (FC2) was chosen as the common comparator. Since fluoropyrimidine plus oxaliplatin doublet (especially capecitabine plus oxaliplatin) was commonly used in clinical applications, we also observed relative results between fluoropyrimidine plus oxaliplatin doublet and other alternative regimens by network league tables. Similar to that of general analysis, the majority of studies featured metastatic and measurable gastric cancer cases, exhibiting a low level of clinical heterogeneity and therefore a well transitivity ([Table 2](#table2-1758835919877726){ref-type="table"}). Overall, none of the included studies were at high risk of bias regarding methodological design ([Supplementary Table 4](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

###### 

Baseline characteristics of eligible studies for additional analysis (unselected population).

![](10.1177_1758835919877726-table2)

  Study                                                Leading country   Registration                  Phase         Enrollment                       Regimen                                                            Node               Sample size              Age                                       Gender (M/F)                              Region                                    Metastatic (Y/N)                          Visceral involvement (Y/N)                Peritoneal involvement (Y/N)   Prior resection (Y/N)   Measurable (Y/N)   PS (0/1/2)      Location (G/J)              Histological type (I/D)    OS-HR                                     PFS-HR                                    ORR (P/T)          hAE (E/T)          non-hAE (E/T)      Journal                                             PMID
  ---------------------------------------------------- ----------------- ----------------------------- ------------- -------------------------------- ------------------------------------------------------------------ ------------------ ------------------------ ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------ ----------------------- ------------------ --------------- --------------------------- -------------------------- ----------------------------------------- ----------------------------------------- ------------------ ------------------ ------------------ --------------------------------------------------- -------------------------------------------
  Kawakami 2018                                        Japan             UMIN000006755                 II            NA                               S-1 plus cisplatin                                                 SC2                41                       68                                        33/8                                      Eastern                                   33/8                                      22/19                                     8/33                           6/35                    NA                 22/19           Gastric                     NA                         0.78 (95% CI, 0.49--1.24)                 0.76 (95% CI, 0.46--1.26)                 21/41              27/39              26/39              Oncologist                                          30115736
  Capecitabine plus cisplatin                          XC2               43                            64            36/7                             38/5                                                               20/23              13/30                    2/41                                      24/19                                     23/43                                     38/43                                     37/43                                                                                                                                                                                                                                                                                                                                                                                       
  Nishikawa 2018                                       Japan             NCT00140624                   II            July 2011--June 2013             Capecitabine plus cisplatin                                        XC2                55                       65                                        45/10                                     Eastern                                   43/12                                     11/44                                     23/32                          17/38                   36/19              45/8/2          Gastric                     19/29                      0.94 (95% CI, 0.62--1.42)                 1.13 (95% CI, 0.75--1.69)                 25/36              23/55              40/55              Eur J Cancer                                        30096702
  S-1 plus cisplatin                                   SC2               55                            65            30/25                            42/13                                                              12/43              23/32                    17/38                                     33/22                                     47/7/1                                    26/24                                     14/33                                     16/55                          39/55                                                                                                                                                                                                                                                                                                              
  Yamada 2018                                          Japan             UMIN000007652                 III           April 2012--March 2016           S-1 plus cisplatin plus docetaxel                                  SC3                370                      Adult                                     NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                 0--1            Gastric                     259/428                    0.99 (95% CI, 0.85--1.16)                 0.99 (95% CI, 0.86--1.15)                 219/370            [245/370-2]{.ul}   [26/370-1]{.ul}    J Clin Oncol                                        J Clin Oncol 36, 2018 (suppl; abstr 4009)
  S-1 plus cisplatin                                   SC2               371                           208/371       [140/371-2]{.ul}                 [27/371-1]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Fuchs 2018                                           USA               NCT02314117                   III           January 2015--May 2017           5-FU/capecitabine plus cisplatin plus ramucirumab                  XC2R               326                      58.9                                      214/112                                   Versatile                                 Metastatic                                NA                                        NA                             NA                      Measurable         0--2            Gastric and junction        NA                         0.96 (95% CI, 0.80--1.16)                 0.75 (95% CI, 0.61--0.94)                 134/326            [125/326-2]{.ul}   [32/326-1]{.ul}    J Clin Oncol                                        10.1200/JCO.2018.36.4_suppl.5
  5-FU/capecitabine plus cisplatin                     XC2               319                           60.1          215/104                          116/319                                                            [131/319-2]{.ul}   [5/319-1]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Ajani 2017                                           USA               NCT01285557                   III           April 2011--August 2014          S-1 plus cisplatin                                                 SC2                239                      56                                        124/115                                   Western                                   Metastatic                                NA                                        NA                             55/184                  193/46             74/165/0        223/16                      **Balanced** ^\*^ **-D**   0.99 (95% CI, 0.76--1.28)                 0.86 (95% CI, 0.65--1.14)                 67/193             138/230            166/230            Ann Oncol                                           28911091
  5-FU plus cisplatin                                  FC2               122                           56            60/62                            34/88                                                              91/31              38/83/0                  117/5                                     18/91                                     50/118                                    84/118                                                                                                                                                                                                                                                                                                                                                                                                                                
  Hall 2017                                            UK                ISCTRN33934807                II            June 2009--January 2011          Capecitabine plus oxaliplatin plus epirubicin                      XO3                17                       **74** ^\*^                               13/4                                      Western                                   17/0                                      NA                                        NA                             NA                      NA                 0/11/6          **10/2/5** ^\*^ **-E**      Balanced                   1 *versus* 2: 1.24 (95% CI, 0.39--3.94)   1 *versus* 2: 0.83 (95% CI, 0.36--1.93)   5/17               NA                 14/17              Br J Cancer                                         28095397
  Capecitabine plus oxaliplatin                        XO2               19                            **77** ^\*^   13/6                             17/2                                                               4/10/5             **5/1/11** ^\*^ **-E**   1 *versus* 3: 0.84 (95% CI, 0.41--1.73)   1 *versus* 3: 0.64 (95% CI, 0.24--1.71)   9/19                                      7/19                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Capecitabine                                         19                **75** ^\*^                   15/4                                           18/1                                                               2/10/7             **7/4/8** ^\*^ **-E**    2 *versus* 3: 0.38 (95% CI, 0.14--1.03)   2 *versus* 3: 0.78 (95% CI, 0.34--1.79)   2/19                                      8/19                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Yoon 2016                                            USA               NCT01246960                   II            April 2011--August 2012          5-FU plus oxaliplatin plus leucovorin plus ramucirumab             FO2R               84                       64.5                                      63/21                                     Western                                   80/4                                      NA                                        NA                             NA                      67/17              40/43/0         **19/26/39** ^\*^ **-E**    Balanced                   1.08 (95% CI, 0.73--1.58)                 0.98 (95% CI, 0.69--1.37)                 38/84              27/82              65/82              Ann Oncol                                           27765757
  5-FU plus oxaliplatin plus leucovorin                FO2               84                            60            61/23                            79/5                                                               70/14              43/41/0                  **20/23/41** ^\*^ **-E**                  39/84                                     31/80                                     35/80                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Shah 2016                                            South Korea       NCT01590719                   II            July 2012--May 2013              5-FU plus oxaliplatin plus leucovorin plus onartuzumab             FO2R               62                       58.5                                      40/22                                     Versatile                                 Metastatic                                NA                                        NA                             23/39                   NA                 24/35/0         46/16                       20/31                      1.06 (95% CI, 0.64--1.75)                 1.08 (95% CI, 0.71--1.63)                 26/43              [41/60-2]{.ul}     [10/60-2]{.ul}     Oncologist                                          27401892
  5-FU plus oxaliplatin plus leucovorin                FO2               61                            57            36/25                            20/41                                                              24/36/0            48/13                    23/26                                     24/42                                     [29/60-2]{.ul}                            [1/60-2]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                         
  Tebbutt 2016                                         Australia         ACTRN12609000109202           II            April 2010--January 20111        5-FU/capecitabine plus cisplatin plus docetaxel plus panitumumab   XC3R               37                       64                                        33/4                                      Western                                   Metastatic and locally unresectable       26/11                                     13/24                          NA                      Measurable         [34/3]{.ul}     **13/10/15** ^\*^ **-E**    Balanced                   1.02 (95% CI, 0.51--2.05)                 1.08 (95% CI, 0.59--2.01)                 22/37              NA                 26/37              Br J Cancer                                         26867157
  5-FU/capecitabine plus cisplatin plus docetaxel      XC3               39                            59            30/9                             23/16                                                              5/34               [37/2]{.ul}              **15/11/13** ^\*^ **-E**                  17/39                                     18/39                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Hironaka 2016                                        Japan             JapicCTI-111635               II            October 2011--December 2012      S-1 plus oxaliplatin plus leucovorin                               SO2                47                       65                                        33/14                                     Eastern                                   40/7                                      NA                                        12/35                          NA                      Measurable         37/10/0         Gastric                     24/23                      1 *versus* 2: 0.76 (95% CI, 0.47--1.24)   1 *versus* 2: 0.52 (95% CI, 0.30--0.88)   31/47              25/47              [28/47-3]{.ul}     Lancet Oncol                                        26640036
  S-1 plus leucovorin                                                    47                            65            37/10                            40/7                                                               11/36              37/10/0                  24/23                                     1 *versus* 3: 0.59 (95% CI, 0.37--0.93)   1 *versus* 3: 0.60 (95% CI, 0.35--1.02)   20/47                                     11/47                                     [10/47-3]{.ul}                                                                                                                                                                                                                                                                                                                                    
  S-1 plus cisplatin                                   SC2               48                            65            38/10                            41/7                                                               14/34              38/10/0                  18/30                                     2 *versus* 3: 0.77 (95% CI, 0.49--1.22)   2 *versus* 3: 1.08 (95% CI, 0.67--1.74)   22/48                                     43/48                                     [22/48-3]{.ul}                                                                                                                                                                                                                                                                                                                                    
  Wang 2016                                            China             NCT00811447                   III           November 2008--June 2012         5-FU plus cisplatin plus docetaxel                                 FC3                119                      56.6                                      81/38                                     Eastern                                   89/30                                     NA                                        NA                             46/73                   Measurable         [115/4]{.ul}    99/20                       Balanced                   0.71 (95% CI, 0.52--0.97)                 0.58 (95% CI, 0.42--0.80)                 58/119             [72/119-1]{.ul}    31/119             Gastric Cancer                                      25604851
  5-FU plus cisplatin                                  FC2               115                           55.5          88/27                            89/26                                                              39/76              [108/7]{.ul}             86/29                                     39/115                                    [11/115-1]{.ul}                           21/115                                                                                                                                                                                                                                                                                                                                                                                                                                
  Ryu 2016                                             South Korea       NCT01671449                   III           October 2012--October 2014       S-1 plus oxaliplatin                                               SO2                338                      56                                        NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      172/166            [331/7]{.ul}    Gastric and junction        NA                         0.86 (95% CI, 0.66--1.11)                 0.85 (95% CI, 0.67--1.07)                 Description        Description        Description        J Clin Oncol                                        10.1200/JCO.2016.34.15_suppl.4015
  S-1 plus cisplatin                                   SC2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Li 2015                                              China             NCT01198392                   III           October 2008--June 2011          S-1 plus cisplatin                                                 SC2                120                      53.2                                      84/36                                     Eastern                                   Metastatic and locally unresectable       NA                                        NA                             65/55                   Measurable         28/85/7         98/22                       Balanced                   1.05 (95% CI, 0.73--1.50)                 1.03 (95% CI, 0.76--1.39)                 27/120             112/120            22/120             Oncotarget                                          26439700
  5-FU plus cisplatin                                  FC2               116                           55.3          85/31                            64/52                                                              29/83/4            106/10                   25/116                                    41/116                                    20/116                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Ochenduszko 2015                                     Poland            NCT02445209                   III           September 2010--February 2014    Capecitabine plus oxaliplatin plus epirubicin                      XO3                29                       57.9                                      16/13                                     Western                                   28/1                                      6/23                                      16/13                          16/13                   Measurable         [26/3]{.ul}     Gastric and junction        5/10                       1.25 (95% CI, 0.72--2.18)                 1.06 (95% CI, 0.63--1.80)                 NA                 25/29              7/29               Med Oncol                                           26354521
  5-FU plus cisplatin plus leucovorin plus docetaxel   FC3               27                            60.3          13/14                            24/3                                                               15/12              12/15                    14/13                                     [25/2]{.ul}                               6/10                                      19/26                                     4/26                                                                                                                                                                                                                                                                                                                                                                                        
  Du 2015                                              China             NCT02370849                   II            October 2009--February 2012      S-1 plus cisplatin plus nimotuzumab                                SC2R               31                       58                                        17/14                                     Eastern                                   22/9                                      6/25                                      4/27                           8/23                    Measurable         5/26/0          25/6                        Balanced                   1.78 (95% CI, 0.97--3.25)                 2.14 (95% CI, 1.19--3.83)                 17/31              8/31               6/31               Medicine                                            26061330
  S-1 plus cisplatin                                   SC2               31                            53            26/5                             18/13                                                              3/28               5/26                     9/22                                      7/24/0                                    25/6                                      18/31                                     4/31                                      1/31                                                                                                                                                                                                                                                                                                                                              
  Van Cutsem 2015                                      Belgium           NCT00382720                   II            September 2006--September 2007   5-FU plus oxaliplatin plus leucovorin plus docetaxel               FO3                89                       58                                        61/28                                     Western                                   Metastatic and locally unresectable       63/26                                     17/72                          35/54                   77/12              [87/2]{.ul}     75/14                       NA                         1 *versus* 2: 0.73 (95% CI, 0.48--1.09)   1 *versus* 2: 0.80 (95% CI, 0.55--1.18)   41/88              [49/88-1]{.ul}     67/88              Ann Oncol                                           25416687
  Capecitabine plus oxaliplatin plus docetaxel         XO3               86                            59            64/22                            50/36                                                              17/69              40/46                    80/6                                      [84/2]{.ul}                               75/11                                     1 *versus* 3: 0.51 (95% CI, 0.35--0.76)   1 *versus* 3: 0.43 (95% CI, 0.30--0.63)   21/81                          [50/82-1]{.ul}          73/82                                                                                                                                                                                                                                                                                      
  Oxaliplatin plus docetaxel                                             79                            59            51/28                            55/24                                                              7/72               23/56                    69/10                                     [77/2]{.ul}                               70/9                                      2 *versus* 3: 0.75 (95% CI, 0.51--1.10)   2 *versus* 3: 0.69 (95% CI, 0.49--0.96)   18/78                          [52/78-1]{.ul}          76/78                                                                                                                                                                                                                                                                                      
  Yamada 2015                                          Japan             JapicCTI-101021               III           January 2010--October 2011       S-1 plus oxaliplatin                                               SO2                318                      65                                        240/78                                    Eastern                                   261/57                                    160/158                                   61/257                         74/244                  Measurable         224/91/3        Gastric                     144/174                    0.96 (95% CI, 0.80--1.14)                 1.00 (95% CI, 0.84--1.20)                 117/318            [151/338-3]{.ul}   174/338            Ann Oncol                                           25316259
                                                                                                                     S-1 plus cisplatin               SC2                                                                324                65                       237/87                                                                              272/52                                    164/160                                   64/260                                    72/252                                                 228/92/4                           145/179                                                                                          169/324                                   [314/335-3]{.ul}   200/335                                                                                   
  Shen 2015                                            China             NCT00887822                   III           March 2009--July 2010            Capecitabine plus cisplatin                                        XC2R               102                      55.5                                      74/28                                     Eastern                                   94/8                                      40/62                                     NA                             20/82                   86/16              [97/5]{.ul}     82/20                       Balanced                   1.11 (95% CI, 0.79--1.56)                 0.89 (95% CI, 0.66--1.21)                 29/86              68/101             45/101             Gastric Cancer                                      24557418
                                                                                                                                                      Capecitabine plus cisplatin plus bevacizumab                       XC2                100                      54.2                                      68/32                                                                               95/5                                      39/61                                                                    24/76                   81/19              [95/5]{.ul}     85/15                                                  33/81                                     54/100                                    66/100                                                                                                       
  Chen 2015                                            China             NA                            NA            August 2009--June 2011           S-1 plus oxaliplatin plus docetaxel                                SO3                30                       18--75                                    18/12                                     Eastern                                   Metastatic                                NA                                        NA                             NA                      Measurable         6/20/4          Gastric                     Balanced                   0.97 (95% CI, 0.78--1.22)                 0.97 (95% CI, 0.87--1.08)                 16/30              8/30               7/30               Chinese Journal of CancerPrevention and Treatment   28850174
                                                                                                                                                      5-FU plus cisplatin plus docetaxel                                 FC3                30                       14/16                                                                                                                                                                                                                                                                                       9/17/4                                                                                                                                                     14/30              6/30               6/30                                                                   
  Iveson 2014                                          UK                NCT00719550                   II            October 2009--June 2010          Capecitabine plus cisplatin plus epirubicin plus rilotumumab       XC3R               82                       61                                        57/25                                     Western                                   73/9                                      NA                                        NA                             13/69                   76/6               34/47/1         66/12                       NA                         0.70 (95% CI, 0.45--1.09)                 0.60 (95% CI, 0.45--0.79)                 30/76              56/81              68/81              Lancet Oncol                                        24965569
                                                                                                                                                      Capecitabine plus cisplatin plus epirubicin                        XC3                39                       60                                        31/8                                                                                34/5                                                                                                                                       9/30               38/1            16/22/1                     31/4                                                                                                           8/38               16/39              32/39                                                                  
  Zhang 2014                                           China             NA                            NA            August 2010--September 2012      S-1 plus oxaliplatin plus cetuximab                                SO2R               30                       49                                        37/19                                     Eastern                                   Metastatic and locally unresectable       26/30                                     8/48                           12/44                   Measurable         3/47/6          Gastric                     25/31                      0.74 (95% CI, 0.42--1.30)                 0.67 (95% CI, 0.38--1.18)                 17/30              10/30              3/30               World J Surg Oncol                                  24758484
                                                                                                                                                      S-1 plus oxaliplatin                                               SO2                26                                                                                                                                                                                                                                                                                                                                                                                                                                    11/26                                     11/26              5/26                                                                                      
  Li 2014                                              China             NA                            NA            NA                               S-1 plus oxaliplatin                                               SO2                16                       42.1                                      9/7                                       Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      Measurable         0--2            Gastric                     Balanced                   Median OS time                            0.78 (95% CI, 0.18--3.39)                 9/16               [2/16-1]{.ul}      NA                 Cancer Research and Clinic                          28850174
                                                                                                                                                      5-FU plus oxaliplatin plus leucovorin                              FO2                16                       45.7                                      11/5                                                                                                                                                                                                                                                                                                                                                               7/16                                      [5/16-1]{.ul}                                                                                                
  Koizumi 2013                                         Japan             JapicCTI-101327               II            December 2008--February 2012     S-1 plus cisplatin plus orantinib                                  SC2R               45                       62                                        30/15                                     Eastern                                   39/6                                      19/26                                     15/30                          NA                      Measurable         28/17/0         Gastric                     22/23                      0.74 (95% CI, 0.46--1.19)                 1.23 (95% CI, 0.74--2.05)                 28/45              [36/45-2]{.ul}     27/45              Br J Cancer                                         24045669
                                                                                                                     S-1 plus cisplatin               SC2                                                                46                 63.5                     35/11                                                                               39/7                                      24/22                                     15/31                                                                                            30/16/0                            25/20                                                                                            26/46                                     [28/46-2]{.ul}     14/46                                                                                     
  Waddell 2013                                         UK                NCT00824785                   III           June 2008--October 2011          Capecitabine plus oxaliplatin plus epirubicin plus panitumumab     XO3R               278                      63                                        232/46                                    Western                                   244/34                                    NA                                        NA                             NA                      Measurable         118/144/16      **78/94/106** ^\*^ **-E**   Balanced                   1.37 (95% CI, 1.07--1.76)                 1.22 (95% CI, 0.98--1.52)                 116/254            69/276             264/276            Lancet Oncol                                        23594787
                                                                                                                                                      Capecitabine plus oxaliplatin plus epirubicin                      XO3                275                      62                                        226/49                                                                              250/25                                                                                                                                                        117/143/15      **89/75/111** ^\*^ **-E**                                                                                                                  100/238            137/266            190/266                                                                
  Lordick 2013                                         Germany           EudraCT2007-004219-75         III           June 2008--December 2010         Capecitabine plus cisplatin plus cetuximab                         XC2R               455                      60                                        339/116                                   Versatile                                 439/16                                    NA                                        113/342                        92/363                  Measurable         237/218/0       376/71                      162/76                     1.00 (95% CI, 0.87--1.17)                 1.09 (95% CI, 0.92--1.29)                 136/455            178/446            430/446            Lancet Oncol                                        23594786
                                                                         Capecitabine plus cisplatin   XC2           449                              59                                                                 334/115                                     436/12                                                                              116/333                                   90/359                                                                              228/220/0                      371/73                  149/94                                                         131/449                    234/436                                   278/436                                                                                                                                                
  Al-Batran 2013                                       Germany           NCT00737373                   II            August 2007--October 2008        5-FU plus oxaliplatin plus leucovorin plus docetaxel               FO3                72                       **69** ^\*^                               51/21                                     Western                                   50/22                                     33/39                                     14/58                          18/54                   Measurable         [67/5]{.ul}     45/27                       NA                         0.83 (95% CI, 0.54--1.28)                 0.80 (95% CI, 0.54--1.20)                 35/72              [59/72-2]{.ul}     58/72              Eur J Cancer                                        23063354
                                                                                                                                                      5-FU plus oxaliplatin plus leucovorin                              FO2                71                       **70** ^\*^                               45/26                                                                               49/22                                     32/39                                     14/57                          18/53                                      [65/6]{.ul}     47/24                                                                                                                                      20/71              [16/70-2]{.ul}     46/70                                                                  
  Kim 2012                                             South Korea       NCT00985556                   II            March 2008--September 2009       S-1 plus oxaliplatin                                               SO2                65                       60                                        44/21                                     Eastern                                   47/18                                     NA                                        NA                             NA                      53/12              11/54/0         Gastric                     Balanced                   1.08 (95% CI, 0.74--1.58)                 1.06 (95% CI, 0.72--1.57)                 21/53              29/65              17/65              Eur J Cancer                                        22243774
                                                                                                                                                      Capecitabine plus oxaliplatin                                      XO2                64                       61                                        45/19                                                                               46/18                                                                                                                                      45/19              8/54/2                                                                                                                                                     20/45              16/64              23/64                                                                  
  Ocvirk 2012                                          Slovenia          ISRCTN34052674                II            January 2003--March 2007         5-FU plus cisplatin plus epirubicin                                FC3                45                       54.7                                      34/11                                     Western                                   37/8                                      7/38                                      13/32                          NA                      NA                 21/21/3         Gastric                     NA                         1.16 (95% CI, 0.75--1.80)                 1.48 (95% CI, 0.94--2.35)                 14/45              14/45              16/45              Am J Clin Oncol                                     21399488
                                                                                                                                                      Capecitabine plus cisplatin plus epirubicin                        XC3                40                       55.6                                      32/8                                                                                35/5                                      5/35                                      12/28                                                                     21/18/2                                                                                                                                                    12/40              12/40              15/40                                                                  
  Ohtsu 2011                                           Japan             NCT00548548                   III           September 2007--December 2008    Capecitabine plus cisplatin plus bevacizumab                       XC2R               387                      58                                        257/130                                   Versatile                                 367/20                                    130/257                                   NA                             110/277                 311/76             [365/22]{.ul}   333/54                      NA                         0.87 (95% CI, 0.73--1.04)                 0.80 (95% CI, 0.68--0.93)                 143/311            194/386            165/386            J Clin Oncol                                        21844504
                                                                                                                                                      Capecitabine plus cisplatin                                        XC2                387                      59                                        258/129                                                                             378/9                                     126/261                                                                  107/280                 297/90             [367/20]{.ul}   338/49                                                                                                                                     111/297            209/381            183/381                                                                
  Li 2011                                              China             NA                            II            January 2003--December 2007      5-FU plus cisplatin plus paclitaxel                                FC3                50                       59                                        32/18                                     Eastern                                   28/22                                     NA                                        NA                             NA                      Measurable         [24/26]{.ul}    Gastric                     Balanced                   1.02 (95% CI, 0.63--1.66)                 NA                                        24/50              [4/50-1]{.ul}      [5/50-1]{.ul}      World J Gastroenterol                               21448363
                                                                                                                                                      5-FU plus oxaliplatin plus leucovorin                              FO2                44                       58                                        31/13                                                                               27/17                                                                                                                                                         [21/23]{.ul}                                                                                                                                               20/44              [4/44-1]{.ul}      [0/44-1]{.ul}                                                          
  Ajani 2010                                           USA               NCT00400179                   III           May 2005--March 2007             S-1 plus cisplatin                                                 SC2                521                      59                                        382/139                                   Western                                   497/24                                    NA                                        NA                             NA                      499/22             226/295/0       438/83                      Balanced                   0.92 (95% CI, 0.80--1.05)                 0.99 (95% CI, 0.86--1.14)                 117/402            254/521            295/521            J Clin Oncol                                        20159816
                                                                                                                                                      5-FU plus cisplatin                                                FC2                508                      60                                        347/161                                                                             488/20                                                                                                                                     485/23             200/308/0       417/91                                                                                                                                     123/385            446/508            422/508                                                                
  Lee 2009                                             South Korea       NA                            III           July 2000--January 2004          5-FU plus heptaplatin                                              FH2                88                       53.5                                      66/22                                     Eastern                                   84/3                                      NA                                        NA                             68/20                   Measurable         36/46/5         Gastric                     NA                         0.83 (95% CI, 0.61--1.11)                 1.22 (95% CI, 0.84--1.77)                 27/78              34/88              38/88              Cancer Res Treat                                    19688066
                                                                                                                                                      5-FU plus cisplatin                                                FC2                86                       53.5                                      62/24                                                                               79/4                                                                                                               68/18                                      30/51/4                                                                                                                                                    28/78              2/86               64/86                                                                  
  Kang 2009                                            South Korea       NA                            III           April 2003--January 2005         Capecitabine plus cisplatin                                        XC2                160                      56                                        103/57                                    Versatile                                 Metastatic and locally unresectable       94/66                                     30/130                         40/120                  Measurable         0--2            Gastric                     NA                         0.85 (95% CI, 0.65--1.11)                 0.80 (95% CI, 0.63--1.03)                 64/139             29/156             38/156             Ann Oncol                                           19153121
                                                                                                                                                      5-FU plus cisplatin                                                FC2                156                      56                                        108/48                                                                              84/72                                     29/127                                                                   34/122                                                                                                                                                      44/137                                    35/155             37/155                                                                                    
  Popov 2008                                           Serbia            NA                            NA            NA                               5-FU plus oxaliplatin plus leucovorin                              FO2                36                       57                                        24/12                                     Western                                   29/7                                      21/15                                     13/23                          27/9                    Measurable         3/22/11         21/15                       Balanced                   0.70 (95% CI, 0.54--0.90)                 0.66 (95% CI, 0.34--1.27)                 15/36              Cycles             Cycles             J BUON                                              19145671
                                                                                                                                                      5-FU plus cisplatin plus leucovorin                                FC2                36                       55                                        26/10                                                                               28/8                                      20/16                                     14/22                          25/11                                      6/20/10         19/17                                                                                                                                      9/36                                                                                                         
  Al-Batran 2008                                       Germany           NA                            III           June 2003--January 2006          5-FU plus oxaliplatin plus leucovorin                              FO2                112                      64                                        64/48                                     Western                                   109/3                                     70/42                                     37/75                          51/71                   NA                 [103/9]{.ul}    92/20                       NA                         0.89 (95% CI, 0.66--1.21)                 0.76 (95% CI, 0.57--0.99)                 39/112             28/112             48/112             J Clin Oncol                                        18349393
                                                                                                                                                      5-FU plus cisplatin plus leucovorin                                FC2                108                      64                                        81/27                                                                                                                                                                                                  98/10                   69/39              30/78           45/63                                                  [97/11]{.ul}                              84/24                                                                                                                                                  
  Cunningham 2008                                      UK                ISRCTN51678883                III           June 2000--May 2005              5-FU plus cisplatin plus epirubicin                                FC3                249                      65                                        202/47                                    Western                                   198/51                                    NA                                        NA                             19/230                  Measurable         [220/29]{.ul}   **90/72/87** ^\*^ **-E**    Balanced                   2 *versus* 1: 0.92 (95% CI, 0.76--1.11)   2 *versus* 1: 0.98 (95% CI, 0.82--1.17)   107/263            161/234            186/234            N Engl J Med                                        18172173
                                                                                                                                                      Capecitabine plus cisplatin plus epirubicin                        XC3                241                      64                                        194/47                                                                              185/56                                                                                                             18/223                                     [211/30]{.ul}   **102/68/71** ^\*^ **-E**                              3 *versus* 1: 0.96 (95% CI, 0.79--1.15)   3 *versus* 1: 0.97 (95% CI, 0.81--1.17)   116/250            171/234            209/234                                                                
                                                                                                                                                      5-FU plus oxaliplatin plus epirubicin                              FO3                235                      61                                        191/44                                                                              181/54                                                                                                             18/217                                     [215/20]{.ul}   **87/55/93** ^\*^ **-E**                               4 *versus* 1: 0.80 (95% CI, 0.66--0.97)   4 *versus* 1: 0.85 (95% CI, 0.70--1.02)   104/245            111/225            181/225                                                                
                                                                                                                                                      Capecitabine plus oxaliplatin plus epirubicin                      XO3                239                      62                                        198/41                                                                              181/58                                                                                                             21/217                                     [215/24]{.ul}   **104/53/82** ^\*^ **-E**                                                                                                                  117/244            112/227            197/227                                                                
  Van Cutsem 2006                                      Belgium           NA                            III           November 1999--January 2003      5-FU plus cisplatin                                                FC2                224                      55                                        158/66                                    Western                                   217/6                                     NA                                        NA                             71/153                  Measurable         29/192/3        168/56                      45/77                      1.29 (95% CI, 1.02--1.63)                 1.47 (95% CI, 1.19--1.82)                 57/224             [126/224-1]{.ul}   [206/224-3]{.ul}   J Clin Oncol                                        17075117
                                                                                                                                                      5-FU plus cisplatin plus docetaxel                                 FC3                221                      55                                                                                                                            159/62                                                                                                             213/6                                      68/153          28/190/3                    179/42                                                                                                         40/92              81/221             [181/221-1]{.ul}   [197/221-3]{.ul}                                    
  Kim 2001                                             South Korea       NA                            III           March 1997--April 2000           5-FU plus cisplatin plus epirubicin                                FC3                61                       55                                        45/15                                     Eastern                                   57/3                                      32/29                                     NA                             NA                      Measurable         [55/6]{.ul}     Gastric                     NA                         0.83 (95% CI, 0.42--1.61)                 Median PFS time                           22/61              [23/61-2]{.ul}     [32/61-3]{.ul}     Eur J Cancer                                        10.1016/S0959-8049(01)81651-8
                                                                                                                                                      5-FU plus cisplatin                                                FC2                60                       56.5                                      42/18                                                                               57/3                                      28/32                                                                                                               [53/7]{.ul}                                                                                                                                                20/60              [10/60-2]{.ul}     [10/60-3]{.ul}                                                         
  KRGGC 1992                                           South Korea       NA                            NA            NA                               5-FU plus cisplatin plus epirubicin                                FC3                25                       NA                                        NA                                        Eastern                                   Metastatic and locally unresectable       NA                                        NA                             NA                      NA                 NA              Gastric                     NA                         0.57 (95% CI, 0.27--1.20)                 NA                                        5/21               Description        Description        Anticancer Res                                      1295444
                                                                                                                                                      5-FU plus cisplatin                                                FC2                22                                                                                                                                                                                                                                                                                                                                                                                                                                    6/22                                                                                                                                                   

**Notes:** Items that may produce significant heterogeneity are emphasized with bold-type letters and asterisks. Underlined data in PS (0/1/2) indicates that the numbers should be interpreted as PS (0 and 1) *versus* PS (2). The additional letter 'E' in certain items of 'Location (G/J)' suggested that there were additional esophageal cancer cases in addition to gastric and gastroesophageal junction cancer cases. The additional letter 'D' in 'Histological type (I/D)' suggested that the study featured diffuse gastric cancer specifically. The word 'Balanced' in 'Histological type (I/D)' indicates that although there was no description about the ratio of intestinal and diffused types, there were other classifications of histological grades and both arms were well balanced. In multi-arm studies, for example, '1 *versus* 2' in survival data referred to the hazard ratio of first regimen *versus* the second regimen. In terms of adverse events, since the number of events sometimes surpassed the total number of patients, therefore in those situations we only calculated the most significant types of adverse event in each category. The numbers of selected types of adverse events were identified inside the cells and underlined. Moreover, the words 'Description' or 'Cycles' inside adverse events suggested that there was no quantitative data or the quantitative data was calculated by chemotherapeutic cycles rather than patient-level comparison, respectively. Regarding 'PMID', those studies without a specific PubMed ID were either replaced by a DOI number or the PubMed ID of previous systematic reviews carrying relevant information. Unless clarified, the hazard ratios were the results of upper arm *versus* lower arm in each trial.

E/T, events/total patients; G/J, gastric/junction; hAE, hematological adverse events; HR, hazard ratio; I/D, intestinal/diffused; M/F, male/female; NA, not available; non-hAE, nonhematological adverse events; ORR, objective response rate; OS, overall survival; PFS: progression-free survival; P/T, responsive patients/total patients; Y/N, yes/no.

**Nodes:** 1, monotherapy; 2, doublet; 3, triplet; S, S-1; C, cisplatin; F, 5-FU; H, heptaplatin; O, oxaliplatin; R, targeted medication; X, capecitabine. Details of the rationale for organizing the nodes are described in the main text.

### Primary endpoint: OS {#section31-1758835919877726}

A total of 38 studies were included in the network calculation. The pooled results were in low heterogeneity and high consistency (*I*^2^ = 0.16%, *Q* heterogeneity: *p* = 0.405, *Q* inconsistency: *p* = 0.508). 'Capecitabine plus cisplatin-based triplet plus targeted medication', '5-FU plus oxaliplatin-based triplet', and 'Capecitabine plus oxaliplatin-based triplet' closely ranked as the top three regimens in the entire hierarchy, all of which displayed superiority against '5-FU plus cisplatin' and 'Capecitabine plus cisplatin'. However, none of them displayed superiority against '5-FU plus oxaliplatin', 'S-1 plus oxaliplatin', or 'Capecitabine plus oxaliplatin' ([Supplementary Figures 6](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726) and [7](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

### Secondary endpoint: PFS {#section32-1758835919877726}

A total of 36 randomized controlled trials were merged into the pooled analysis. Again, 'Capecitabine plus cisplatin-based triplet plus targeted medication', '5-FU plus oxaliplatin-based triplet', and 'Capecitabine plus oxaliplatin-based triplet' were the best three nodes in the rankings, statistically superior to '5-FU plus cisplatin' and 'Capecitabine plus cisplatin'. In addition, except for 'Capecitabine plus cisplatin-based triplet plus targeted medication', none of the top three regimens demonstrated enough advantage against '5-FU plus oxaliplatin', 'S-1 plus oxaliplatin', or 'Capecitabine plus oxaliplatin' ([Supplementary Figures 8](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726) and [9](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

### Secondary endpoint: ORR {#section33-1758835919877726}

A total of 37 studies were eligible for the network calculation. 'Capecitabine plus cisplatin-based triplet plus targeted medication', '5-FU plus oxaliplatin-based triplet', and 'Capecitabine plus cisplatin plus targeted medication' reigned the hierarchy with statistical advantage against '5-FU plus cisplatin'. However, none of them displayed superiority against '5-FU plus oxaliplatin', 'S-1 plus oxaliplatin', or 'Capecitabine plus oxaliplatin' ([Supplementary Figures 10](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726) and [11](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

### Secondary endpoint: hematological adverse events {#section34-1758835919877726}

A total of 34 trials were included into the pooled analysis. 'Capecitabine plus cisplatin-based triplet plus targeted medication' appeared to have statistical inferiority against '5-FU plus cisplatin', '5-FU plus oxaliplatin', 'S-1 plus oxaliplatin', and 'Capecitabine plus oxaliplatin' ([Supplementary Figures 12](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726) and [13](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

### Secondary endpoint: nonhematological adverse events {#section35-1758835919877726}

A total of 35 studies were eligible for network meta-analysis. 'Capecitabine plus cisplatin-based triplet plus targeted medication' was statistically inferior to 'S-1 plus oxaliplatin' while comparable to '5-FU plus cisplatin', '5-FU plus oxaliplatin,' and 'Capecitabine plus oxaliplatin' ([Supplementary Figures 14](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726) and [15](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

Patients with specific positivity {#section36-1758835919877726}
---------------------------------

There were a total of eight randomized controlled trials were analyzed in this section of the systematic review, including four HER-2 positive studies, two MET-1 positive studies, one CLDN18.2 positive study, and one EGFR positive study ([Table 3](#table3-1758835919877726){ref-type="table"}). None of the included studies were at high risk of bias with regard to methodological design ([Supplementary Table 5](https://journals.sagepub.com/doi/suppl/10.1177/1758835919877726)).

###### 

Baseline characteristics of eligible studies for patients with specific positivity.

![](10.1177_1758835919877726-table3)

  Study                                                Leading country   Registration   Phase     Enrollment                      Regimen                                                              Sample size             Age                        Gender (M/F)   Region                      Metastatic (Y/N)                      Visceral involvement (Y/N)   Peritoneal involvement (Y/N)   Prior resection (Y/N)   Measurable (Y/N)   PS (0/1/2)      Location (G/J)              Histological type (I/D)   OS-HR                       PFS-HR                      ORR (P/T)   hAE (E/T)     non-hAE (E/T)   Journal                      PMID
  ---------------------------------------------------- ----------------- -------------- --------- ------------------------------- -------------------------------------------------------------------- ----------------------- -------------------------- -------------- --------------------------- ------------------------------------- ---------------------------- ------------------------------ ----------------------- ------------------ --------------- --------------------------- ------------------------- --------------------------- --------------------------- ----------- ------------- --------------- ---------------------------- --------------------------
  Tabernero 2018                                       USA               NCT01774786    III       June 2013--January 2016         5-FU/Capecitabine plus cisplatin plus trastruzumab plus pertuzumab   388                     62                         294/94         Versatile                   Metastatic                            NA                           NA                             NA                      351/37             162/226/0       278/110                     353/18                    0.84 (95% CI, 0.71--1.00)   0.73 (95% CI, 0.62--0.86)   199/351     218/385       335/385         Lancet Oncol                 30217672
  5-FU/Capecitabine plus cisplatin plus trastruzumab   392               61             323/69    352/40                          162/229/0                                                            294/98                  350/21                     170/352        220/388                     241/388                                                                                                                                                                                                                                                                                                                                           
  Moehler 2018                                         Germany           NCT01123473    II        February 2011--August 2013      5-FU/Capecitabine plus cisplatin plus epirubicin plus lapatinib      14                      66                         12/2           Western                     Metastatic                            NA                           NA                             NA                      NA                 10/4/0          10/4                        Balanced                  0.90 (95% CI, 0.35--2.27)   0.86 (95% CI, 0.37-1.99)    6/14        7/14          11/14           Cancer Chemother Pharmacol   30105460
  5-FU/Capecitabine plus cisplatin plus epirubicin     14                58             10/4      9/5/0                           10/4                                                                 3/14                    4/14                       14/14                                                                                                                                                                                                                                                                                                                                                                                        
  Hecht 2016                                           USA               NCT00680901    III       June 2008--January 2012         Capecitabine plus oxaliplatin plus lapatinib                         249                     61                         189/60         Versatile                   236/13                                NA                           NA                             18/231                  NA                 79/149/21       **214/23/12** ^\*^ **-E**   225/9                     0.91 (95% CI, 0.73--1.12)   0.84 (95% CI, 0.69--1.03)   131/249     17/270        113/270         J Clin Oncol                 26628478
  Capecitabine plus oxaliplatin                        238               59             176/62    227/11                          20/218                                                               63/153/22               **210/20/8** ^\*^ **-E**   211/10         93/238                      7/267                                 75/267                                                                                                                                                                                                                                                                                                      
  Bang 2010                                            South Korea       NCT01041404    III       September 2005--December 2008   5-FU/Capecitabine plus cisplatin plus trastruzumab                   294                     59.4                       226/68         Versatile                   284/10                                NA                           NA                             71/223                  269/25             [264/30]{.ul}   236/58                      225/26                    0.74 (95% CI, 0.60--0.91)   0.71 (95% CI, 0.59--0.85)   139/294     144/294       173/294         Lancet                       20728210
  5-FU/Capecitabine plus cisplatin                     290               58.5           218/72    280/10                          62/228                                                               257/33                  [263/27]{.ul}              242/48         213/2                       100/290                               134/290                      140/290                                                                                                                                                                                                                                                                        
  Catenacci 2017                                       UK                NCT01697072    III       November 2012--November 2014    Capecitabine plus cisplatin plus epirubicin plus rilotumumab         304                     61                         205/99         Western                     284/20                                118/186                      NA                             48/256                  262/42             117/187/0       **227/53/24** ^\*^ **-E**   Balanced                  1.34 (95% CI, 1.10--1.63)   1.26 (95% CI, 1.04--1.51)   78/262      130/298       182/298         Lancet Oncol                 28958504
  Capecitabine plus cisplatin plus epirubicin          305               59             220/85    283/22                          136/169                                                              48/257                  267/38                     115/189/1      **195/71/39** ^\*^ **-E**   119/267                               148/299                      169/299                                                                                                                                                                                                                                                                        
  Shah 2017                                            UK                NCT01662869    III       November 2012--March 2014       5-FU plus oxaliplatin plus leucovorin plus onartuzumab               279                     60                         188/91         Versatile                   Metastatic                            NA                           NA                             98/181                  Measurable         112/162/0       214/65                      136/83                    0.82 (95% CI, 0.59--1.15)   0.90 (95% CI, 0.71--1.16)   84/207      124/279       101/279         JAMA Oncol                   27918764
  5-FU plus oxaliplatin plus leucovorin                283               58             183/100   101/182                         118/158/0                                                            218/65                  133/98                     100/217        100/280                     80/280                                                                                                                                                                                                                                                                                                                                            
  Schuler 2016                                         Germany           NCT01630083    II        NA                              Capecitabine plus oxaliplatin plus epirubicin plus IMAB362           161                     58                         NA             Western                     Metastatic and locally unresectable   NA                           NA                             NA                      NA                 NA              257/65                      106/141                   0.51 (95% CI, 0.36--0.73)   0.47 (95% CI, 0.31--0.70)   69/161      Description   Description     Ann Oncol                    10.1093/annonc/mdw371.06
  Capecitabine plus oxaliplatin plus epirubicin        161               45/161                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Rao 2010                                             UK                NCT00215644    II        August 2005--November 2006      Capecitabine plus cisplatin plus epirubicin plus matuzumab           35                      59                         24/11          Western                     Metastatic                            NA                           10/25                          NA                      NA                 13/22/0         **14/21** ^\*^ **-E**       Balanced                  1.02 (95% CI, 0.61--1.70)   1.13 (95% CI, 0.63--2.01)   11/35       16/35         31/35           Ann Oncol                    20497967
  Capecitabine plus cisplatin plus epirubicin          36                64             27/9      9/27                            12/24/0                                                              **16/20** ^\*^ **-E**   21/36                      17/36          24/36                                                                                                                                                                                                                                                                                                                                                                         

**Notes:** Items that may produce significant heterogeneity are emphasized with bold-type letters and asterisks. Underlined data in PS (0/1/2) indicates that the numbers should be interpreted as PS (0 and 1) *versus* PS (2). The additional letter 'E' in certain items of 'Location (G/J)' suggested that there were additional esophageal cancer cases besides of gastric and gastroesophageal junction cancer cases. The word 'Balanced' in 'Histological type (I/D)' indicated that although there was no description about the ratio of intestinal and diffused types, there were other classifications of histological grades and both arms were well balanced. Moreover, the words 'Description' or 'Cycles' inside adverse events suggested that there was no quantitative data or the quantitative data was calculated by chemotherapeutic cycles rather than patient-level comparison, respectively. Regarding 'PMID', those studies without a specific PubMed ID were either replaced by a DOI number or the PubMed ID of previous systematic reviews carrying relevant information. Unless clarified, the hazard ratios were the results of upper arm *versus* lower arm in each trial.

E/T, events/total patients; G/J, gastric/junction; hAE, hematological adverse events; HR, hazard ratio; I/D, intestinal/diffused; M/F, male/female; NA, not available; non-hAE, non-hematological adverse events; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; P/T, responsive patients/total patients; Y/N, yes/no.

### HER-2 positive {#section37-1758835919877726}

Three studies were large-scale phase III randomized controlled trials and only one trial reported phase II results, with sample sizes ranging from 28 to 780 patients. According to Bang *et al*,^[@bibr40-1758835919877726]^ adding trastuzumab to capecitabine plus cisplatin could significantly enhance its survival benefits among HER-2 positive patients compared with capecitabine plus cisplatin alone (OS HR: 0.74 \[95% CI, 0.60--0.91\]; PFS HR: 0.71 \[95% CI, 0.59--0.85\]). Recently, Tabernero *et al*.^[@bibr41-1758835919877726]^ also confirmed that dual HER-2 targeting strategy with both pertuzumab and trastuzumab failed to generate OS benefit compared with trastuzumab-based regimen, despite the difference of OS coming close to crossing the boundary value (OS HR: 0.84 (95% CI, 0.71--1.00); PFS HR: 0.73 (95% CI, 0.62--0.86)). Moreover, either pertuzumab or trastuzumab was well tolerable compared with its control arm. On the other hand, however, adding lapatinib failed to produce survival benefits in contrast to capecitabine plus oxaliplatin alone^[@bibr42-1758835919877726]^ (OS HR: 0.91 \[95% CI, 0.73--1.12\]; PFS HR: 0.84 \[95% CI, 0.69--1.03\]), irrespective of gastric (*p* = 0.30), gastroesophageal junction (*p* = 0.77), or esophageal cancer subgroups (*p* = 0.77). Similarly, the addition of lapatinib to capecitabine-based triplet also failed to have enough survival benefit (OS HR: 0.90 \[95% CI, 0.35--2.27\]; PFS HR: 0.86 \[95% CI, 0.37--1.99\]), despite that the results were less credible owing to lower statistical power on small sample size (*n* = 28)^[@bibr43-1758835919877726]^ ([Table 3](#table3-1758835919877726){ref-type="table"}).

### MET-1 positive {#section38-1758835919877726}

Two large-scale phase III randomized controlled trials reported the first-line options for MET-1-positive gastric cancer patients. Based on 609 patients, Catenacci *et al*.^[@bibr44-1758835919877726]^ surprisingly described that adding rilotumumab not only failed to increase but also significantly decreased the survival time among MET-1-positive patients compared with capecitabine plus cisplatin plus epirubicin alone (OS HR: 1.34 \[95% CI, 1.10--1.63\]; PFS HR: 1.26 \[95% CI, 1.04--1.51\]). Furthermore, Shah *et al*.^[@bibr45-1758835919877726]^ reported that addition of onartuzumab also failed to display survival benefit among MET-1-positive patients compared to 5-FU plus oxaliplatin plus leucovorin alone (OS HR: 0.82 \[95% CI, 0.59--1.15\]; PFS HR: 0.90 \[95% CI, 0.71--1.16\]) ([Table 3](#table3-1758835919877726){ref-type="table"}).

### Others {#section39-1758835919877726}

Based on a CLDN18.2-positive 161-patient phase II trial, adding IMAB362 could significantly enhance the survival time while maintaining comparable tolerability against capecitabine plus oxaliplatin plus epirubicin alone^[@bibr46-1758835919877726]^ (OS HR: 0.51 \[95% CI, 0.36--0.73\]; PFS HR: 0.47 \[95% CI, 0.31--0.70\]). For EGFR-positive patients, the addition of matuzumab failed to generate survival benefits compared with capecitabine plus cisplatin plus epirubicin alone^[@bibr47-1758835919877726]^ (OS HR: 1.02 \[95% CI, 0.61--1.70\]; PFS HR: 1.13 \[95% CI, 0.63--2.01\]) ([Table 3](#table3-1758835919877726){ref-type="table"}).

Discussion {#section40-1758835919877726}
==========

Currently, systemic therapy is still the preferred measure against advanced inoperable gastric cancer, in which fluoropyrimidine plus cisplatin doublet is the most recommended regimen in virtue of both clinical efficacy and tolerability.^[@bibr5-1758835919877726]^ However, previously published systematic reviews failed to make a panoramic summary about the systemic therapy against gastric cancer, let alone a credible hierarchical ranking that fit the diversity of regimens.^[@bibr16-1758835919877726][@bibr17-1758835919877726]--[@bibr18-1758835919877726]^ Therefore, we have conducted by far the most comprehensive systematic review and network meta-analysis based on 119 high-quality randomized controlled trials, covering both chemotherapy and targeted medications.

In general, analysis among unselected population, 'fluoropyrimidine plus platinum-based triplet' was the top-ranking node regarding OS, which was consistent with the result of pairwise meta-analysis and was confirmed to be stable by sensitivity analysis. In terms of PFS and ORR, 'fluoropyrimidine plus platinum-based triplet plus targeted medication' and 'fluoropyrimidine plus platinum-based triplet' ranked as the top two nodes, demonstrating statistical superiority against 'fluoropyrimidine plus platinum doublet'. However, in 2014, one ASCO expert meeting stated that a risk reduction of HR 0.80 might be clinically relevant. In addition, the ESMO clinical benefit scale even recommends that HR 0.65 is clinically relevant. Therefore, in consideration of survival efficacy and safety profile, it is still inappropriate to conclude that 'fluoropyrimidine plus platinum doublet' could be replaced by 'fluoropyrimidine plus platinum-based triplet' in terms of first-line regimens. Moreover, since the general analysis did not further clarify different subtypes inside fluoropyrimidine and platinum, we still had concerns about the statistical credibility about the pooled results and, thus, we performed a specific additional analysis.

The additional analysis that individualized different types of fluoropyrimidine and platinum gave detailed comparisons across diverse fluoropyrimidine and platinum-based regimens. Concerning survival benefits, 'capecitabine plus cisplatin-based triplet plus targeted medication' was the best regimen in the entire hierarchy, statistically superior against both '5-FU plus cisplatin' and 'capecitabine plus cisplatin' while comparable with '5-FU plus oxaliplatin', 'S-1 plus oxaliplatin', and 'Capecitabine plus oxaliplatin'. On the other hand, it also featured unfavorable tolerability as expected, especially compared with 'S-1 plus oxaliplatin'. However, although more specific categorizations helped to lower heterogeneity, it also raised concerns about low statistical power owing to the small sample-size in each node. In addition, the third component and targeted medication besides fluoropyrimidine and platinum were not always consistent within the same node, which could introduce heterogeneity into the final results as well. Therefore, we feel that it is more appropriate to maintain the recommendation of fluoropyrimidine plus oxaliplatin doublet (especially capecitabine or S-1) as the preferred first-line regimen, which has been widely applied in clinical settings.

Among patients with specific pathological positivity, HER-2 is the most widely investigated target against advanced gastric cancer. Based on a large-scale phase III randomized controlled trial by Bang *et al*.,^[@bibr40-1758835919877726]^ the addition of trastuzumab to fluoropyrimidine plus cisplatin doublet has been confirmed as the preferred regimen against HER-2 overexpressing metastatic gastric cancer. Despite the negative result of OS (*p* = 0.056), a dual HER-2-targeting strategy with both pertuzumab and trastuzumab displayed a significant benefit in terms of PFS, as well as the comparable tolerability compared with trastuzumab-based first-line regimen.^[@bibr41-1758835919877726]^ Since the difference in OS was quite close to statistical boundary, it hinted that other combination of dual HER-2-targeting strategy might possibly reach statistical significance in future designs. In addition, lapatinib plus capecitabine plus oxaliplatin failed to surpass capecitabine plus oxaliplatin doublet,^[@bibr42-1758835919877726]^ therefore fluoropyrimidine plus cisplatin plus trastuzumab is still the best regimen for HER-2 overexpressing advanced gastric cancer at present. According to two large-scale phase III studies, adding rilotumumab or onartuzumab failed to generate survival benefits among MET-1-positive patients compared with fluoropyrimidine plus platinum-based chemotherapy alone.^[@bibr44-1758835919877726],[@bibr45-1758835919877726]^ This suggests that fluoropyrimidine plus cisplatin may still serve as the preferred first-line regimen against MET-1-positive advanced gastric cancer. Moreover, in a phase II trial by Schuler *et al*.^[@bibr46-1758835919877726]^, the addition of IMAB362 significantly elongated survival lifespan among patients with CLDN18.2 positivity compared with capecitabine plus oxaliplatin plus epirubicin alone. Since CLDN18.2 is believed to widely exist in nearly half of gastric cancer cells, IMAB362 is a very promising medication and, thus, a phase III trial is currently ongoing.

Although our systematic review was rigorously designed and conducted, there were still some limitations within. First, this network meta-analysis was not based on individual-patient data. However, since the network was verified to be highly consistent, stable, and homogenous, conclusions of our pooled analysis were therefore also credible and applicable. Second, even though in additional analysis, several different regimens were still forced to merge into one node in order to perform the network calculations, since the third component and targeted medication in addition to fluoropyrimidine and platinum were not further specified. All these could bring potential biases into the network meta-analysis despite of the low overall statistical heterogeneity as mentioned previously. Third, the overall number of studies especially for top-ranking nodes such as 'capecitabine plus cisplatin-based triplet plus targeted medication' were still inadequate, which might lower the statistical power of the entire quantitative analysis.

Taken together, fluoropyrimidine plus oxaliplatin doublet (especially capecitabine or S-1) should still be considered as the preferred first-line regimen owing to its comparable survival benefits and lower toxicity.
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